Cochrane
Library

Cochrane Database of Systematic Reviews

Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock (Review)

Andriolo BNG, Andriolo RB, Salomão R, Atallah ÁN

Andriolo BNG, Andriolo RB, Salomão R, Atallah ÁN.

Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD010959.

DOI: [10.1002/14651858.CD010959.pub2](https://doi.org/10.1002/14651858.CD010959.pub2).

www.cochranelibrary.com

Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock (Review)

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	6
OBJECTIVES	6
METHODS	7
RESULTS	9
Figure 1.	10
Figure 2.	12
Figure 3.	13
Figure 4.	15
Figure 5.	17
Figure 6.	18
Figure 7.	18
Figure 8.	18
DISCUSSION	19
AUTHORS' CONCLUSIONS	21
ACKNOWLEDGEMENTS	21
REFERENCES	22
CHARACTERISTICS OF STUDIES	27
DATA AND ANALYSES	45
Analysis 1.1. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 1 Mortality at longest follow-up.	46
Analysis 1.2. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 2 Mortality at 28 days.	47
Analysis 1.3. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 3 Mortality at ICU discharge.	47
Analysis 1.4. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 4 Mortality at hospital discharge.	47
Analysis 1.5. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 5 Time receiving antimicrobial therapy (days) - mean (SD).	48
Analysis 1.6. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 6 Time receiving antimicrobial therapy (days) - median (IQR).	48
Analysis 2.1. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 1 Hospital length of stay (days) - median (IQR) or mean (SD).	49
Analysis 2.2. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 2 ICU length of stay (days) - mean (SD).	49
Analysis 2.3. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 3 ICU length of stay (days) - median (IQR).	50
Analysis 2.4. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 4 SOFA score during ICU stay.	50
Analysis 2.5. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 5 SOFA score at day 3.	50
Analysis 2.6. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 6 SOFA score at day 5.	50
Analysis 2.7. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 7 SOFamax score.	50
Analysis 2.8. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 8 APACHE II score.	51
Analysis 2.9. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 9 Reinfection (primary infection relapse).	51
Analysis 2.10. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 10 Duration of mechanical ventilation (days).	51
Analysis 3.1. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 1 Mortality at 5 days.	54
Analysis 3.2. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 2 Mortality at 14 days.	54
Analysis 3.3. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 3 Mortality at 90 days.	54
Analysis 3.4. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 4 Sepsis-related death*.	54

Analysis 3.5. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 5 Septic shock-related death.	54
Analysis 3.6. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 6 Patients on antibiotics at day 5 (last information carried over for non-survivors).	54
Analysis 3.7. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 7 Patients on antibiotics at day 5 (non-survivors considered as being treated with antibiotic).	55
Analysis 3.8. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 8 Patients on antibiotics at day 1 (among survivals).	55
Analysis 3.9. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 9 Patients on antibiotics at day 5 (survivors only).	55
Analysis 3.10. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 10 Therapy withdrawn in hospital.	55
Analysis 3.11. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 11 Appropriate empirical antibiotics.	55
Analysis 3.12. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 12 Empirical antibiotic initiation ≤ 6 hours.	55
Analysis 3.13. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 13 Empirical antibiotic initiation > 6 hours.	56
Analysis 3.14. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 14 Infection at day 3.	56
Analysis 3.15. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 15 Infection at day 5.	56
Analysis 3.16. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 16 Infection at any time point after randomization.	56
Analysis 3.17. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 17 Nasal swabs positive for methicillin-resistant <i>Staphylococcus aureus</i> .	56
Analysis 3.18. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 18 Rectal swabs positive for extended-spectrum β -lactamase-resistant.	56
Analysis 3.19. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 19 Rectal swabs positive for <i>Enterobacter</i> , <i>Klebsiella</i> .	56
Analysis 3.20. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 20 Readmission due to secondary infection.	57
Analysis 3.21. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 21 Isolates with multi-resistant organisms.	57
Analysis 3.22. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 22 Nosocomial infection.	57
Analysis 3.23. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 23 Antibiotic therapy-free days (mean, SD) - PCT vs standard care.	57
Analysis 3.24. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 24 Antibiotic therapy-free days (median, IQR) - PCT vs standard care.	57
Analysis 3.25. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 25 Antibiotic therapy-free days - PCT vs CRP.	58
Analysis 3.26. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 26 Duration of first episode of antibiotic treatment (days)*.	58
Analysis 3.27. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 27 Days of antibiotic exposure per 1000 inpatient days.	58
Analysis 3.28. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 28 All antibiotics total daily defined dose Irrespective of the antimicrobial.	58
Analysis 3.29. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 29 Antibiotics "stopped earlier" (hazard ratio).	58
Analysis 3.30. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 30 Antibiotics "stopped earlier" (hazard ratio) adjusted for disease severity.	58
Analysis 3.31. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 31 Time to antibiotic cessation at day 28.	59
Analysis 3.32. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 32 Duration of first episode of antibiotic treatment (days).	59
Analysis 3.33. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 33 Antibiotic therapy-free days according to different subgroups.	59
Analysis 3.34. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 34 World Health Organization daily defined dose per 100 occupied bed days.	59

Analysis 3.35. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 35 Antibiotics maintained for 7 days because of bacteraemia and/or a SOFA score above 10 at inclusion.	59
Analysis 3.36. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 36 Antibiotic therapy discontinuation in the first episode of infection*.	60
Analysis 3.37. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 37 Protocol overruling.	60
Analysis 3.38. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 38 Clinical cure*.	60
Analysis 3.39. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 39 Total costs with antibiotics per comparison group (USD).	60
Analysis 3.40. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 40 Mean cost with antibiotics + PCT kit per participant (USD).	60
Analysis 3.41. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 41 Cost reduction for antibiotic treatment.	61
Analysis 4.1. Comparison 4 PCT versus non-PCT (standard care or CRP: ITT analysis), Outcome 1 Mortality at longest follow-up (imputing mortality for missing participants).	61
APPENDICES	61
WHAT'S NEW	66
CONTRIBUTIONS OF AUTHORS	66
DECLARATIONS OF INTEREST	67
SOURCES OF SUPPORT	67
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	67
NOTES	67
INDEX TERMS	67

[Intervention Review]

Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock

Brenda NG Andriolo¹, Regis B Andriolo², Reinaldo Salomão³, Álvaro N Atallah¹¹Cochrane Brazil, Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde, São Paulo, Brazil.²Department of Public Health, Universidade do Estado do Pará, Belém, Brazil. ³Department of Medicine, Universidade Federal de São Paulo, São Paulo, Brazil**Contact address:** Regis B Andriolo, Department of Public Health, Universidade do Estado do Pará, Travessa Perebebuí, 2623, Belém, Pará, 66087-670, Brazil. regis.andriolo@gmail.com.**Editorial group:** Cochrane Emergency and Critical Care Group.**Publication status and date:** Edited (no change to conclusions), published in Issue 1, 2019.**Citation:** Andriolo BNG, Andriolo RB, Salomão R, Atallah ÁN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. *Cochrane Database of Systematic Reviews* 2017, Issue 1. Art. No.: CD010959. DOI: [10.1002/14651858.CD010959.pub2](https://doi.org/10.1002/14651858.CD010959.pub2).

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Serum procalcitonin (PCT) evaluation has been proposed for early diagnosis and accurate staging and to guide decisions regarding patients with sepsis, severe sepsis and septic shock, with possible reduction in mortality.

Objectives

To assess the effectiveness and safety of serum PCT evaluation for reducing mortality and duration of antimicrobial therapy in adults with sepsis, severe sepsis or septic shock.

Search methods

We searched the Central Register of Controlled Trials (CENTRAL; 2015, Issue 7); MEDLINE (1950 to July 2015); Embase (Ovid SP, 1980 to July 2015); Latin American Caribbean Health Sciences Literature (LILACS via BIREME, 1982 to July 2015); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCO host, 1982 to July 2015), and trial registers (ISRCTN registry, ClinicalTrials.gov and CenterWatch, to July 2015). We reran the search in October 2016. We added three studies of interest to a list of 'Studies awaiting classification' and will incorporate these into formal review findings during the review update.

Selection criteria

We included only randomized controlled trials (RCTs) testing PCT-guided decisions in at least one of the comparison arms for adults (≥ 18 years old) with sepsis, severe sepsis or septic shock, according to international definitions and irrespective of the setting.

Data collection and analysis

Two review authors extracted study data and assessed the methodological quality of included studies. We conducted meta-analysis with random-effects models for the following primary outcomes: mortality and time spent receiving antimicrobial therapy in hospital and in the intensive care unit (ICU), as well as time spent on mechanical ventilation and change in antimicrobial regimen from a broad to a narrower spectrum.

Main results

We included 10 trials with 1215 participants. Low-quality evidence showed no significant differences in mortality at longest follow-up (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.65 to 1.01; $I^2 = 10\%$; 10 trials; $N = 1156$), at 28 days (RR 0.89, 95% CI 0.61 to 1.31; $I^2 = 0\%$; four

trials; $N = 316$), at ICU discharge (RR 1.03, 95% CI 0.50 to 2.11; $I^2 = 49\%$; three trials; $N = 506$) and at hospital discharge (RR 0.98, 95% CI 0.75 to 1.27; $I^2 = 0\%$; seven trials; $N = 805$; moderate-quality evidence). However, mean time receiving antimicrobial therapy in the intervention groups was -1.28 days (95% CI to -1.95 to -0.61; $I^2 = 86\%$; four trials; $N = 313$; very low-quality evidence). No primary study has analysed the change in antimicrobial regimen from a broad to a narrower spectrum.

Authors' conclusions

Up-to-date evidence of very low to moderate quality, with insufficient sample power per outcome, does not clearly support the use of procalcitonin-guided antimicrobial therapy to minimize mortality, mechanical ventilation, clinical severity, reinfection or duration of antimicrobial therapy of patients with septic conditions.

PLAIN LANGUAGE SUMMARY

Procalcitonin evaluation for reducing mortality in adults with sepsis

Review question

Is procalcitonin evaluation effective in reducing mortality and time receiving antimicrobial therapy in adults with sepsis?

Background

Sepsis is defined as confirmed or suspected infection associated with a systemic inflammatory response syndrome (SIRS). This condition can evolve to an acute organ dysfunction, known as 'severe sepsis'; or to persistent hypotension, even after adequate fluid replacement, known as 'septic shock'. Procalcitonin (PCT) is a biological indicator in the blood that has been found to increase during blood infection. We wanted to assess whether evaluation of PCT can reduce mortality and time receiving antimicrobial therapy in adults with blood infection. To this end, we compared PCT versus nothing, versus standard care (only usual clinical judgement) and versus other blood chemical indicators. Nowadays, other chemical indicators include C-reactive protein (CRP), interleukins and neopterin.

Study characteristics

The evidence is current to July 2015. However, we reran the search in October 2016 and will incorporate the three studies of interest when we update the review. For this version, we included 10 studies in this review. These studies were carried out in Australia, Brazil, China, Czech Republic, France, Germany, Indonesia and Switzerland. Researchers evaluated participants from academic and non-academic surgical, general and trauma intensive care units (ICUs) and emergency departments. All studies analysed adults with confirmed or presumed blood infection. Comparisons were most commonly based on 'standard care', but one trial used CRP-guided antibiotic therapy. In six trials, study authors had worked as consultants for, and/or received payments from, companies involved in the procalcitonin analysis.

Key results

Results showed no significant differences in mortality at longest follow-up (124/573; 21.6% versus 152/583; 26.1%), at 28 days (37/160; 23.1% versus 39/156; 25%), at ICU discharge (28/247; 11.3% versus 25/259; 9.6%) or at hospital discharge (82/398; 20.6% versus 81/407; 19.9%), respectively, for PCT and non-PCT groups. Also, researchers found no differences in mechanical ventilation, clinical severity, reinfection or duration of antimicrobial therapy. No study provided information about participants for whom the antimicrobial regimen was changed from a broad to a narrower spectrum.

Quality of the evidence

We considered the body of available evidence as having very low to moderate quality owing to absence of methods to prevent errors during studies or absence of information about such methods, as well as possibly insufficient numbers of studies and patients per outcome. Additionally, the authors of most studies worked as consultants and/or received payments from companies involved in the procalcitonin analysis.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. PCT versus non-PCT (standard care or CRP: primary outcomes) for reducing mortality in adult patients with sepsis, severe sepsis and septic shock

Patient or population: adult patients with sepsis, severe sepsis and septic shock

Settings: emergency departments, as well as general medical and surgical, academic and non-academic ICUs from Australia, Brazil, China, Czech Republic, France, Germany, Indonesia and Switzerland

Intervention: PCT versus non-PCT (standard care or CRP: primary outcomes)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with non-PCT (standard care or CRP: primary outcomes)	Risk with PCT				
Mortality at longest follow-up	Study population		RR 0.81 (0.65 to 1.01)	1156 (10 RCTs)	⊕⊕⊕⊖ Low ^a	70% of studies (7/10) were considered to have high risk of bias in at least 2 criteria, 50% (5/10) low risk of bias in at least 3 criteria and 50% (5/10) unclear risk of bias in at least 1 criterion, including randomization. We observed no asymmetry in the funnel plot.
	261 per 1000	211 per 1000 (169 to 263)				
Mortality at 28 days	Study population		RR 0.89 (0.61 to 1.31)	316 (4 RCTs)	⊕⊕⊕⊖ Low ^b	25% of studies (1/4) were considered to have unclear risk of bias for random sequence generation, 25% (1/4) unclear risk of bias for allocation concealment and 100% (4/4) unclear or high risk of bias for blinding of participants and outcome assessors. Confidence interval was considered relatively high (from 0.61 to 1.31).
	250 per 1000	223 per 1000 (153 to 328)				
Mortality at ICU discharge	Study population		RR 1.03 (0.50 to 2.11)	506 (3 RCTs)	⊕⊕⊕⊖ Low ^b	All studies (3/3) were considered to have low risk of bias for random sequence generation, 33% (1/3) high risk of bias for allocation concealment and 100% (3/3) unclear or high risk of bias for blinding of participants and outcome assessors. $I^2 = 49\%$ (heterogeneity test). Relatively large confidence interval was 0.50 to 2.11.
	97 per 1000	99 per 1000 (48 to 204)				

Mortality at hospital discharge	Study population		RR 0.98 (0.75 to 1.27)	805 (7 RCTs)	⊕⊕⊕⊖ Moderate ^c	28% of studies (2/7) were considered to have unclear risk of bias for random sequence generation, 42.8% (3/7) unclear or high risk of bias for allocation concealment and 100% (7/7) unclear or high risk of bias for blinding of participants and outcome assessors.
	199 per 1000	195 per 1000 (149 to 253)				
Time receiving antimicrobial therapy (days) - mean (SD)	The mean time receiving antimicrobial therapy (days) - mean (SD) was 8.09 (1.36) days	The mean time receiving antimicrobial therapy (days) - mean (SD) in the intervention group was 1.28 days lower (1.95 lower to 0.61 lower)	-	313 (4 RCTs)	⊕⊖⊖⊖ Very low ^d	75% of studies (3/4) were considered to have unclear risk of bias for both random sequence generation and allocation concealment; 100% (4/4) unclear or high risk of bias for blinding of both participants and outcome assessors and 25% (1/4) unclear risk of bias for incomplete outcome data. $I^2 > 50\%$ (heterogeneity test indicating important heterogeneity between studies). Relatively large 95% confidence interval was 0.61 to 1.95 days. Combined study results show relevant reductions in time receiving antimicrobial therapy of 1.28 days, which varied from 0.61 days to 1.95 days; individual studies showed mean differences from 0.9 to 2 days.
Participants with antimicrobial regimen changed from a broad to a narrower spectrum	Not available from primary studies					

***The risk in the intervention group** (and its 95% confidence interval) is based on assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to the estimate of effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^a GRADE was downrated by two levels for risk of bias.

^b GRADE was downrated by two levels: by one level for risk of bias; and by one level for imprecision.

^c GRADE was downrated by one level for risk of bias.

^d GRADE was downrated by four levels: by one level for risk of bias; by one level four imprecision; and by two levels for inconsistency.

BACKGROUND

Description of the condition

Sepsis is defined as confirmed or suspected infection associated with a systemic inflammatory response syndrome (SIRS) (Dellinger 2013). This condition can evolve to an acute organ dysfunction or tissue hypoperfusion, known as severe sepsis, or to persistent hypotension or vasopressor requirement, even after adequate fluid resuscitation, known as septic shock (Bone 2009; Dellinger 2013).

According to a comprehensive review, the occurrence of septic conditions has been considered high, with incidence rates ranging from 11 to 300/100,000 inhabitants per year, depending on the severity of the systemic infection and the geographic region of patients (Jawad 2012), with 15 to 19 million cases worldwide reported per year (Adhikari 2010). Mortality rates can reach approximately 30% for sepsis, 50% for severe sepsis and 80% for septic shock (Jawad 2012; Salvo 1995; Silva 2004). However, studies evaluating the incidence, prevalence and mortality of sepsis can be biased strongly by the absence of rigour or even the lack of adequate knowledge among healthcare professionals about identification of SIRS, sepsis, severe sepsis and septic shock (Assunção 2010; Klein 2012). Moreover, such conditions are associated with high costs (Lagu 2012; Vaughan-Sarrazin 2011) and bad prognoses, including low quality of life and high mortality, even after hospital discharge (Azevedo 2012; Cuthbertson 2013; Karlsson 2009).

Therapeutic approaches for sepsis include early and appropriate antimicrobial agents, fluid resuscitation and strategies for achieving adequate blood (arterial and venous) pressure, myocardial function, glucose levels and control of infectious foci (Dellinger 2013; Kuehn 2013; Machado 2013; Rivers 2012). However, the success of such early therapeutic approaches depends on rapid results of clinical and laboratory assessments, which usually include body temperature, heart rate, glycaemia, respiratory rate, mental status, white blood cells, partial pressure of oxygen in arterial blood, creatinine and lactate (Dellinger 2013; Levy 2003). Therefore, clinicians have used additional biomarkers in an attempt to diagnose the condition and drive the best therapeutic strategies at the most appropriate moment for patients with sepsis. The most thoroughly investigated biomarkers for specific infectious diseases are the interleukins, C-reactive protein (CRP), procalcitonin (PCT) and neopterin (Tasdelen 2010; Tsalik 2012; Uusitalo-Seppälä 2011). Some of these have been planned to be rigorously evaluated in other Cochrane systematic reviews (Shaikh 2011; Suresh 2013).

Description of the intervention

During the course of an inflammatory event, including systemic infection, several physiological and biochemical changes occur (Hosein 2011; Lichtenstern 2012; Salluh 2011). One of these changes is an increase in production of PCT, especially, but not exclusively, in cases of bacterial infection (Chalupa 2011; Gendrel 1999; McCann 2012; Redl 2000; te Witt 2012). However, some non-infectious conditions, such as trauma, surgery, hyperthermia and neoplasm, can be associated with elevated procalcitonin levels (Becker 2008). The peptide PCT is a precursor of the calcitonin hormone, which is responsible for control of blood concentrations of calcium. Under physiological conditions, PCT is produced by the thyroid gland, but in inflammatory conditions, such as sepsis, virtually any type of cell

can synthesize PCT (Morgenthaler 2003). Expression and liberation of PCT probably are stimulated by different cytokines and microbial by-products (Zannoni 2012).

According to results from up to 30 studies included in two systematic reviews, serum PCT evaluation has revealed values of sensitivity ranging from 55% to 97% (with pooled sensitivity of 77%) and values of specificity from 55% to 93% (with pooled specificity of 79%), as compared with definitions provided by the American College of Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference, the German Sepsis Society or microbiological culture (Tang 2007; Wacker 2013). However, irrespective of accuracy properties, serum PCT evaluation is an important health technology that should be evaluated in the area of 'stratified medicine research' (Hingorani 2013). Serum procalcitonin evaluation can possibly permit early detection of sepsis and determination of the appropriate antimicrobial regimen, including, but not restricted to, antimicrobial timing and spectrum. An important outcome already observed with the serum procalcitonin evaluation can include lower hospital costs, but studies have reported no consistent differences in mortality nor in length of stay in the intensive care unit (ICU) (Maravić-Stojković 2011; Schuetz 2012; Tang 2009).

How the intervention might work

Serum PCT evaluation has been proposed for early diagnosis and accurate staging of sepsis, which can contribute to early decisions, optimal care (Kenzaka 2012; Matthaïou 2012) and, consequently, better outcomes for patients with sepsis, severe sepsis and septic shock (Kumar 2010). Thus, the core 'action mechanism' of serum PCT evaluation consists of altered decisions in the care of patients with sepsis, severe sepsis and septic shock, based on test results, with possible reduction in the risk of bad outcomes. The core of this logical sequence of events is that serum PCT evaluation, not drugs or usual care, is the technology being tested (Hingorani 2013).

Why it is important to do this review

According to Rodger 2012, evaluation of the accuracy of a diagnostic test is not sufficient to prove its effectiveness, safety or efficiency. Corroborating this concept, Hingorani 2013 emphasized that the existence of a factor that predicts differential treatment response does not guarantee that it will be effective when used as a test in clinical practice to inform therapeutic decisions. Therefore, it is of extreme importance that all available evidence on the effectiveness, safety and efficiency of the serum PCT evaluation as a health technology for patients with sepsis, severe sepsis and septic shock is scrutinized. We plan to perform a Cochrane systematic review of randomized controlled trials (RCTs) on this clinical question that can be updated to summarize the main findings for clinical practice.

OBJECTIVES

To assess the effectiveness and safety of serum PCT evaluation for reducing mortality and duration of antimicrobial therapy in adults with sepsis, severe sepsis or septic shock.

METHODS

Criteria for considering studies for this review

Types of studies

We included RCTs and quasi-randomized trials (allocation not considered strictly random), irrespective of language and publication year. We excluded cross-over trials because of the nature of both the intervention and the clinical condition of interest for this review.

Types of participants

We included adults (≥ 18 years old) with sepsis, severe sepsis or septic shock, according to international definitions, irrespective of health specialty (e.g. ward, outpatient clinic, ICU, emergency department). We accepted the following definitions.

1. Sepsis: confirmed or suspected infection associated with a systemic inflammatory response syndrome (SIRS).
2. Severe sepsis: sepsis associated with acute organ dysfunction.
3. Septic shock: sepsis associated with tissue hypoperfusion and persistent hypotension, or vasopressor requirement, even after adequate fluid resuscitation (Bone 2009; Dellinger 2013).

Types of interventions

We considered studies that performed serum PCT evaluation in at least one comparison group. We expected three possible comparison groups based on diagnostic and staging methods: (i) standard methods used routinely to diagnose and stage sepsis; (ii) serum PCT evaluation or PCT-guided therapy algorithm; and (iii) other biomarkers (e.g. CRP, interleukins, pentraxin). On the basis of these groups, we expected the following possible comparisons.

1. i + ii versus i.
2. i + ii versus i + iii.
3. i + ii + iii versus i.
4. i + ii + iii versus i + iii.
5. i + ii versus i + ii (different PCT-guided therapy algorithms).

Types of outcome measures

Primary outcomes

1. Mortality at up to 28 days, in the ICU, in hospital (from sepsis or all causes) and at longest follow-up.
2. Time receiving antimicrobial therapy (in days) or quantity (volume) of antimicrobial agents received.
3. Change in antimicrobial regimen from a broad to a narrower spectrum.

Secondary outcomes

1. Hospital length of stay (days).
2. ICU length of stay (days).
3. Clinical severity of participant's condition, assessed by validated instruments such as the Acute Physiology and Chronic Health Evaluation II (APACHE II) and the Sequential Organ Failure Assessment (SOFA).
4. New infection, as defined by a new SIRS event by reason of a new micro-organism detected after resolution of the initial infection, involving the same infectious focus or a different infectious

focus; or reinfection, as defined by a new SIRS event by reason of the same micro-organism detected after resolution of the initial infection, involving the same infectious focus or a different infectious focus.

5. Duration of mechanical ventilation (days).

Search methods for identification of studies

Electronic searches

Two review authors searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7; Appendix 1); MEDLINE (via PubMed, 1950 to July 2015; Appendix 2); Embase (Ovid SP, 1980 to July 2015; Appendix 3); the Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCO host, 1982 to July 2015); and the Latin American Caribbean Health Sciences Literature (LILACS via BIREME, 1982 to July 2015; Appendix 5). Additionally, we reran the search in October 2016. We added three new studies of interest to a list of [Studies awaiting classification](#) and will incorporate these into formal review findings during the review update.

We used a systematic and sensitive search strategy with search terms for sepsis, severe sepsis, septic shock, procalcitonin evaluation and randomized controlled trials (Appendix 2). We applied no restrictions based on language or date of publication.

Searching other resources

We handsearched the reference lists of reviews, randomized and non-randomized studies and editorials to look for additional studies. We contacted the lead authors of studies and experts in this field to ask about missed, unreported or ongoing studies. We searched for ongoing clinical trials and unpublished studies on the following Internet sites (July 2015).

1. <http://www.controlled-trials.com>.
2. <http://clinicaltrials.gov>.
3. <http://www.centerwatch.com>.

Data collection and analysis

Selection of studies

After excluding duplicates, two review authors (BNGA and RBA) independently assessed all titles and abstracts of studies retrieved by the search strategy to determine their relevance for possible inclusion. We resolved disagreements by discussion with a third review author (RS).

Data extraction and management

Two review authors (BNGA and RBA) independently extracted data from each study using a previously prepared data extraction form that includes specific characteristics of each study (Appendix 6). We described as the 'primary reference' the first publication of each study with more than one publication, and as 'secondary references' all other publications, but we extracted data from all references onto the same extraction sheet.

Assessment of risk of bias in included studies

Two review authors (RBA and BNGA) assessed risk of bias on the basis of criteria described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We assessed the quality of RCTs according to the following domain-based evaluation.

1. Was the allocation sequence adequately generated?
2. Was allocation adequately concealed?
3. Was knowledge of the allocated intervention adequately prevented during the study?
4. Were incomplete outcome data adequately addressed?
5. Are reports of the study free of the suggestion of selective outcome reporting?
6. Was the study apparently free of other problems that could put it at high risk of bias?

We classified each domain as 'low risk of bias' when the authors of primary studies reported methods to prevent bias; as 'unclear risk of bias' when risk of bias was uncertain; and as 'high risk of bias' when the authors of primary studies clearly had not prevented risk of bias.

We reported these assessments for each individual study in the 'Risk of bias' table.

We contacted study author(s) to ask for clarification if we had any uncertainty regarding study data.

Measures of treatment effect

For dichotomous data (e.g. mortality rates), we calculated risk ratios (RRs). In case the effect estimates were statistically significant, we calculated the number needed to treat for an additional beneficial outcome (NNTB) (Christensen 2006). We calculated mean differences (MDs) for continuous data (e.g. hospital length of stay, ICU length of stay). However, some data were presented in isolation, as they were reported in the primary studies. Thus, we reported some continuous data as medians and respective ranges or interquartile ranges (e.g. time receiving antimicrobial therapy, hospital and ICU length of stay, duration of mechanical ventilation in days). Similarly, we presented some dichotomous data as hazard ratios (HRs) with their respective 95% confidence intervals (CIs) (e.g. antibiotic therapy discontinuation). We reported effect estimates from continuous and dichotomous data as P values and 95% CIs for both individual and pooled data (see [Data synthesis](#)).

We planned to contact study author(s) to ask for clarification if we had any uncertainty regarding estimated effects (including but not restricted to data reported only in graphs).

Unit of analysis issues

The individual participant was the unit of analysis inclusively in analyses of cluster-randomized controlled trials. When this was the case, we used direct effect estimates obtained from individual studies (and respective confidence intervals) and combined them in a meta-analysis using the generic inverse variance method.

Dealing with missing data

If it was possible to assess the real number of randomly assigned participants (by reading the publication or by contacting study authors), we intended to perform intention-to-treat (ITT) analyses for dichotomous data. We assumed the worst outcome for all participants who withdrew from/dropped out of the study (see [Sensitivity analysis](#)).

Assessment of heterogeneity

We evaluated the consistency of estimated effects from individual studies by calculating I^2 (Higgins 2011). The I^2 statistic describes approximately the proportion of variation in point estimates that is due to heterogeneity rather than to sampling error. We evaluated the degree of heterogeneity according to the following thresholds.

1. 0% to 40%: may not be important.
2. 30% to 60%: may represent moderate heterogeneity.
3. 50% to 90%: may represent substantial heterogeneity.
4. 75% to 100%: represents considerable heterogeneity.

Assessment of reporting biases

We planned to assess reporting bias by visually inspecting the funnel plot to detect the presence of asymmetry, if we included in the review more than 10 studies per outcome.

Data synthesis

Meta-analytical data synthesis

When more than one study reported continuous and dichotomous data, we pooled results by using the fixed-effect meta-analysis model when we noted no substantial statistical heterogeneity, and the random-effects meta-analysis model when statistical heterogeneity between included studies was substantial (see [Assessment of heterogeneity](#)). We pooled continuous data by using the weighted average of differences between comparison groups, wherein outcomes published for more than one study were assessed on the same scales. If data were reported on different scales that could not be adjusted to a uniform scale, we planned to analyse them by using the standardized mean difference (SMD). We performed a post hoc trial sequential analysis (TSA) to quantify the reliability of cumulative data in meta-analyses (Brok 2009; Wetterslev 2008).

Synthesis of dichotomous and continuous data without sufficient information to insert into a forest plot

When estimated effects were reported without sufficient information for insertion into a forest plot, such as numbers of participants, numbers of events, means, standard deviations and standard errors, as well as effect estimates for non-parametric data (e.g. range, median, percentiles), we reported the data separately in tables in the [Data collection and analysis](#) section (not in forest plots).

Synthesis of the quality of the body of evidence

We used the principles of the GRADE approach (Guyatt 2008) to assess the quality of the body of evidence for our primary outcomes of mortality at 28 days, mortality at ICU discharge, mortality at hospital discharge and time receiving antimicrobial therapy. We imported effect estimates from RevMan 5.3 to GRADE profiler (GRADEpro 2014) to create [Summary of findings for the main comparison](#). This table provides outcome-specific information concerning the overall quality of evidence from studies included in the comparison, the magnitude of effect of interventions examined and the sum of available data on outcomes that we considered. The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item assessed. The quality of a body of evidence is based on different items,

which reflect within-study risk of bias (methodological quality), directness of evidence, heterogeneity of data, precision of effect estimates and risk of publication bias. Thus, we considered each of these items as having 'no limitation', 'serious limitation' or 'very serious limitation' (by downgrading them respectively for one or two levels), resulting in one of the following four overall qualities of evidence for each outcome: 'high', 'moderate', 'low' or 'very low' quality.

Subgroup analysis and investigation of heterogeneity

We planned to compare the possible subgroups below.

1. Diagnostic criteria for sepsis, severe sepsis and septic shock.
2. Participants with sepsis, severe sepsis or septic shock.
3. Infection foci, including respiratory, surgical, bloodstream, catheter, urinary and others.
4. Different cut-off points for PCT to guide the antimicrobial regimen for any absolute reduction in PCT level, any relative reduction in PCT level or any threshold of PCT level.
5. Participants attended by different health specialties (e.g. emergency, ICU, ward).
6. PCT-guided antibiotic commencement versus PCT-guided antibiotic stewardship. It is important to note that multiple subgroup analyses may generate misleading results, but the review authors judged it improbable that included studies would provide sufficient information to permit analyses of all six of these subgroups.

However, we performed no subgroup analyses in this version of the review because of (1) the absence of statistical heterogeneity in the meta-analysis or (2) the absence of a sufficient number of studies with the same specific characteristics to be combined in the same subgroup.

Sensitivity analysis

We planned to examine the robustness of results by excluding and including trials on the basis of risk of bias of included studies, and by considering quasi-randomized controlled trials. We also planned to compare random-effects and fixed-effect estimates only for the primary outcomes, as well as intention-to-treat analysis versus available data analysis (refer to [Dealing with missing data](#)). However, risks of bias were highly diverse among the included studies, no quasi-RCT was localized and studies were clinically and methodologically heterogeneous, which justified the use of random-effects meta-analysis only. Thus, we performed sensitivity analysis only for ITT versus available data analyses for the present version of this systematic review. We assumed poor outcomes for missing data, as supported by the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#)).

RESULTS

Description of studies

Results of the search

The search across all databases yielded 1068 titles. When we excluded duplicate references, we found that we had 740 articles. Of these 740 articles, we excluded 699 because they did not focus on the use of procalcitonin for adults with sepsis, severe sepsis or septic shock, as stated in their titles or abstracts. Of the remaining 41 full-text articles, we excluded 25 that were derived from 22 studies because of study design. Thus, 16 articles had the potential to be included in the review ([Figure 1](#)). Of these 16 articles, we obtained four (derived from three studies) through the search strategy that we reran across all databases in October 2016 ([Bloos 2016](#); [de Jong 2016](#); [Najafi 2015](#)). We contacted the main authors of four of the remaining 12 articles ([Dharaniyadewi 2013](#); [Hochreiter 2009](#); [Liu 2013](#); [Schroeder 2009](#)) to request further information, as outlined in the [Characteristics of included studies](#) table.

Figure 1. Study flow diagram.

Figure 1. (Continued)

Included studies

We included in this review 12 articles derived from 10 trials (1215 participants). These trials were carried out in France (one; [Annane 2013](#)), Brazil (two; [Deliberato 2013](#); [Oliveira 2013](#)), Indonesia (one; [Dharaniyadewi 2013](#)), Germany (two; [Hochreiter 2009](#); [Schroeder 2009](#)), China (one; [Liu 2013](#)), Switzerland (one; [Nobre 2008](#)), Czech Republic (one; [Svoboda 2007](#)) and Australia (one; [Shehabi 2014](#)). Five trials were multi-centre RCTs ([Annane 2013](#); [Nobre 2008](#); [Oliveira 2013](#); [Shehabi 2014](#); [Svoboda 2007](#)). Three studies included participants from surgical ICUs ([Deliberato 2013](#); [Hochreiter 2009](#); [Schroeder 2009](#)), but [Schroeder 2009](#) specifically considered participants who had undergone abdominal surgery. [Nobre 2008](#) included participants from both general/medical and surgical ICUs. [Svoboda 2007](#) included participants with trauma. Three trials were carried out in academic health services ([Liu 2013](#); [Nobre 2008](#); [Oliveira 2013](#)). One trial ([Shehabi 2014](#)) referred to its participants as derived from both academic and non-academic ICUs.

Although they showed some variation in their manner of describing the inclusion criteria, all trials included in this systematic review mentioned adults with confirmed or presumed sepsis, severe sepsis and/or septic shock, according to criteria usually accepted by international consensus ([ACCP/SCCM Consensus Conference Committee 1992](#); [Bone 1992](#); [Levy 2003](#)).

The procalcitonin algorithms were relatively diverse. In general, the authors used PCT drops from 25% to 90% together with PCT thresholds ranging from 0.1 to 2.0 ng/mL ([Annane 2013](#); [Deliberato 2013](#); [Hochreiter 2009](#); [Liu 2013](#); [Nobre 2008](#); [Oliveira 2013](#); [Schroeder 2009](#); [Shehabi 2014](#); [Svoboda 2007](#)). Four authors have also considered other clinical signs and symptoms ([Hochreiter 2009](#); [Schroeder 2009](#); [Shehabi 2014](#); [Svoboda 2007](#)). [Dharaniyadewi 2013](#) provided no PCT algorithm in the paper or in the protocol available from [ClinicalTrials.gov](#) (NCT01862185).

Control arms were referred to most commonly as 'standard care', which was generally based on local epidemiology and susceptibility of micro-organisms, infectious foci, routine clinical evaluation or other criteria based on different guidelines previously implemented in the health service ([Annane 2013](#); [Deliberato 2013](#); [Dharaniyadewi 2013](#); [Hochreiter 2009](#); [Liu 2013](#); [Nobre 2008](#); [Svoboda 2007](#)). Just one study used a CRP-guided algorithm, in which antimicrobial therapy was stopped when CRP levels dropped by > 50% or when CRP < 25 mg/dL was reached but the participant's PCT concentrations were not known ([Oliveira 2013](#)).

For more detailed information about the studies included in this review, please refer to [Characteristics of included studies](#).

Excluded studies

On the basis of study design and inclusion criteria, we excluded 25 articles that had been generated from 22 studies. Six were systematic reviews ([Kopterides 2010](#); [Mann 2011](#); [Prkno 2013](#); [Sandifer 2012](#); [Schuetz 2011](#); [Soni 2013](#)); three were narrative reviews ([Pantelidou 2015](#); [Schuetz 2013](#); [Ternhag 2010](#)); three RCTs included neonates ([Kolici 2013](#); [Stocker 2010a](#); [Stocker 2010b](#)); one RCT had inclusion criteria strict for febrile neutropenia ([Lima 2016](#)); three were RCTs (which generated six articles) with inclusion criteria not specific for sepsis, severe sepsis and/or septic shock ([Bouadma 2010](#); [Jensen 2011](#); [Layios 2012](#)); two used a retrospective study design ([Bodmann 2016](#); [Kiehntopf 2011](#)); and four performed economic evaluations ([Bréchet 2015](#); [Harrison 2015](#); [Kip 2015](#); [Westwood 2015](#)).

For more detailed information about the excluded studies, please refer to the [Characteristics of excluded studies](#) table.

Studies awaiting classification

Although results of this systematic review are based on the search from July 2015, a new search carried out in October 2016 revealed three new studies of interest, which we will incorporate into formal review findings during the review update. Two multi-centre ([Bloos 2016](#); [de Jong 2016](#)) and one single-centre ([Najafi 2015](#)) RCTs were carried out in 35 medical ICUs in Germany ([Bloos 2016](#)), 15 in Netherlands ([de Jong 2016](#)) and one in Tehran ([Najafi 2015](#)). These trials included a total of 2695 participants. [Bloos 2016](#) was the only 2 × 2 factorial study that included use of high-dose intravenous sodium selenite in patients with severe sepsis or septic shock, according to ACCP/SCCM criteria. The other two studies included participants with an antimicrobial regimen initiated for suspected or proven infection on admission or during ICU stay ([de Jong 2016](#)) and for SIRS ([Najafi 2015](#)).

The interventions offered by [Bloos 2016](#) consisted of a PCT-based algorithm (with or without sodium selenite) versus antimicrobial therapy, according to the discretion of the responsible physician (with no PCT usage), also with or without sodium selenite. [de Jong 2016](#) and [Najafi 2015](#) randomized participants to PCT-guided antimicrobial therapy via different algorithms or to standard treatment (non-PCT groups). These three studies measured mortality at different follow-up times and in different settings (e.g.

at 28 days, at one year, in ICU, in hospital). For additional details, see [Characteristics of studies awaiting classification](#).

Ongoing studies

We found no studies awaiting classification.

Risk of bias in included studies

Please see [Characteristics of included studies](#), Figure 2 and Figure 3.

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Annane 2013	+	+	-	-	+	+	+
Deliberato 2013	+	-	-	-	+	+	+
Dharaniyadewi 2013	?	?	?	?	+	-	-
Hochreiter 2009	?	-	-	-	+	+	+
Liu 2013	?	?	?	?	?	+	+
Nobre 2008	+	+	-	-	+	+	+
Oliveira 2013	+	+	-	-	+	+	+
Schroeder 2009	?	?	?	?	+	+	+
Shehabi 2014	+	+	-	-	+	+	+
Svoboda 2007	+	+	?	?	+	+	+

Allocation

Random sequence generation

We considered six trials as having low risk of bias regarding random sequence generation because study authors used random methods. The most frequently reported method was based on electronic random processes generally referred to as “computer-generated random numbers” (Annane 2013; Nobre 2008; Oliveira 2013; Shehabi 2014; Svoboda 2007), but Deliberato 2013 reported that two authors of the trial randomly drew folders from a black box to assign participants to a “PCT group” or a “standard group”. We considered the other four trials to have unclear risk of bias because they did not specify any method of randomization (Dharaniyadewi 2013; Hochreiter 2009; Liu 2013; Schroeder 2009).

We tried without success to contact the authors of four trials by email to obtain detailed information about the method used for random sequence generation (Dharaniyadewi 2013; Hochreiter 2009; Liu 2013; Schroeder 2009) (please refer to [Characteristics of included studies](#) for details).

Allocation concealment

Three trials provided no information regarding allocation concealment methods (Dharaniyadewi 2013; Liu 2013; Schroeder 2009), thus we considered them as having unclear risk of bias. Four trials used methods associated with low risk of bias for allocation concealment (Annane 2013; Nobre 2008; Shehabi 2014; Svoboda 2007). Annane 2013 and Shehabi 2014 reported the use of web-based central randomization. Two trials used opaque, sealed and numbered envelopes (Nobre 2008; Svoboda 2007). We considered two trials as having high risk of bias (Deliberato 2013; Hochreiter 2009). One of them used a method that does not prevent exemption in the randomization process because study authors performed randomization by drawing folders from a box to assign participants to comparison groups (Deliberato 2013). Given that Hochreiter 2009 provided no description of the method used to randomize participant assignments, and that study authors clearly reported the study as open label, we have also assumed that this study has high risk of bias.

We tried without success to contact the authors of four trials by email to obtain detailed information about the method used for allocation concealment (Dharaniyadewi 2013; Hochreiter 2009; Liu 2013; Schroeder 2009).

Blinding

Performance bias

Personnel involved in the trials were clearly unblinded to assignments in six trials (Annane 2013; Deliberato 2013; Hochreiter 2009; Nobre 2008; Oliveira 2013; Shehabi 2014), thus we considered these trials as having high risk of performance bias. We classified four trials as having unclear risk of performance bias because study authors provided no information regarding blinding of personnel and participants (Dharaniyadewi 2013; Liu 2013; Schroeder 2009; Svoboda 2007).

Detection bias

Four trials (Dharaniyadewi 2013; Liu 2013; Schroeder 2009; Svoboda 2007) provided no information with regard to blinding of outcome assessors, and we considered them as having unclear risk of detection bias. We considered six trials as having high

risk of detection bias because study authors reported that outcome assessors were not blinded (Annane 2013; Deliberato 2013; Hochreiter 2009; Nobre 2008; Oliveira 2013; Shehabi 2014).

Incomplete outcome data

We considered all included trials as having low risk of attrition bias because they described a clear flow of participants from randomization to outcome assessment, along with low withdrawal rates, with the exception of one trial with unclear risk of attrition bias (Liu 2013), which provided neither information about withdrawals nor a description of a clear flow of participants within the trial.

Selective reporting

We considered all trials as having low risk of reporting bias because investigators evaluated clinically relevant outcomes. Additionally, four trials made their protocols available along with previously planned outcomes in an electronic repository of research protocols ([clinicaltrials.gov](#)) (Annane 2013; Nobre 2008; Oliveira 2013; Shehabi 2014).

Other potential sources of bias

Nine trials were associated with no suspected additional source of bias, and we considered them as having low risk of bias (Annane 2013; Deliberato 2013; Hochreiter 2009; Liu 2013; Nobre 2008; Oliveira 2013; Schroeder 2009; Shehabi 2014; Svoboda 2007), along with one study for which the authors did not provide a detailed PCT algorithm for dealing with antimicrobial therapies (Dharaniyadewi 2013).

Effects of interventions

See: [Summary of findings for the main comparison](#) PCT versus non-PCT (standard care or CRP: primary outcomes) for reducing mortality in adult patients with sepsis, severe sepsis and septic shock

Primary outcomes

1. Mortality

1.1 Mortality at longest follow-up

Ten trials when combined into a meta-analysis (Annane 2013; Deliberato 2013; Dharaniyadewi 2013; Hochreiter 2009; Liu 2013; Nobre 2008; Oliveira 2013; Schroeder 2009; Shehabi 2014; Svoboda 2007) showed no significant differences in mortality at longest follow-up between PCT (124/573; 21.6%) and non-PCT (152/583; 26.1%) groups with RR of 0.81 (95% CI 0.65 to 1.01; $I^2 = 10\%$; [Analysis 1.1](#)). One trial compared mortality rates between the procalcitonin group (21/49; 42.8%) and the CRP-monitoring group (21/45; 46.6%) (Oliveira 2013) and reported no differences between comparison groups (RR 0.92, 95% CI 0.59 to 1.44). We downgraded the evidence from high to low quality because risk of bias from primary studies was downgraded by two levels.

A post hoc TSA for mortality at longest follow-up with inclusion of trials with no events (zero event adjustment of 0.001 constant), type 1 error of 5% and power of 80% resulted in a TSA-adjusted RR of 0.80 (95% CI 0.65 to 0.98; $I^2 = 0\%$; diversity (D^2) = 0%). On the basis of mortality incidence of 26.07% in the control arm and risk reduction of 17.1%, the required information size is 2853. With 1156 participants included at this time, only 40.52% of the

required information size has been reached. Additionally, TSA is designed for trials with low risk of bias, and given that all included trials had high risk of bias, the true required information size may very well be higher than reported here, but a large trial with low

risk of bias in favour of the intervention may equally reduce the required information size. Additionally, the TSA figure shows that the conventional boundary was not crossed and no significant benefit favoured the intervention (Figure 4).

Figure 4. Trial sequential analysis for mortality at longest follow-up (available data analysis).

1.2 Mortality at 28 days

Four trials combined into a meta-analysis (Liu 2013; Nobre 2008; Oliveira 2013; Svoboda 2007) showed no significant differences in mortality at 28 days between PCT (37/160; 23.1%) and non-PCT (39/156; 25.0%) comparison groups (RR 0.89, 95% CI 0.61 to 1.31; four trials; N = 316; $I^2 = 0\%$) (Analysis 1.2). One trial compared mortality rates between the procalcitonin group (16/49; 32.6%) and the CRP-monitoring group (15/45; 33.3%) (Oliveira 2013) and reported no difference between comparison groups (RR 0.98, 95% CI 0.55 to 1.74). We downgraded the evidence from high to low quality because risk of bias from primary studies was downgraded by one level, and imprecision was downgraded by one level.

1.3 Mortality at ICU discharge

After we combined effect estimates from three trials (Annane 2013; Deliberato 2013; Shehabi 2014) in a meta-analysis, we found no significant differences in mortality at ICU discharge (RR 1.03, 95% CI 0.50 to 2.11; $I^2 = 49\%$) (Analysis 1.3). We downgraded the evidence from high to low quality because risk of bias and imprecision from primary studies were downgraded by one level.

1.4 Mortality at hospital discharge

Irrespective of whether comparison arms provided procalcitonin versus non-procalcitonin (standard care) or procalcitonin versus CRP-guided antimicrobial therapy (Oliveira 2013), a meta-analysis combining seven trials (Annane 2013; Deliberato 2013; Hochreiter 2009; Nobre 2008; Oliveira 2013; Schroeder 2009; Shehabi 2014)

showed absence of differences between them (RR 0.98, 95% CI 0.75 to 1.27; $I^2 = 0\%$; Analysis 1.4). We downgraded the evidence from high to moderate quality because risk of bias and imprecision from primary studies were downgraded by one level.

2. Time receiving antimicrobial therapy (in days) or quantity (volume) of antimicrobial agents received

A meta-analysis that combined four trials evaluating the duration of antimicrobial therapy in days (Hochreiter 2009; Oliveira 2013; Liu 2013; Schroeder 2009) resulted in a reduction of -1.28 mean days (95% CI -1.95 to -0.61; $I^2 = 86\%$) in the procalcitonin group as compared with the non-procalcitonin group (Analysis 1.5).

Even after Oliveira 2013 was removed from the analysis because investigators compared procalcitonin versus CRP, heterogeneity remained and the effect estimate did not change significantly (-1.60 mean days, 95% CI -2.18 to -1.01; $I^2 = 84\%$). When we combined only Hochreiter 2009 and Schroeder 2009 in a meta-analysis, the inconsistency test (I^2 statistic) dropped to 0%, but the effect estimate remained very close to that observed before Liu 2013 and Oliveira 2013 were excluded, as shown by a mean reduction of -1.91 days (95% CI -2.29 to -1.52; $I^2 = 0\%$). Still with regard to duration of antibiotic treatment, Oliveira 2013 observed 13 median days (interquartile range (IQR) 7 to 18) in the procalcitonin group and eight median days (IQR 6 to 18) in the CRP-guided antimicrobial therapy group, but without statistical significance in the comparison between groups ($P = 0.183$), as reported by study authors (Analysis 1.6).

We downgraded the evidence from high to very low quality because risk of bias was downgraded by one level, imprecision by one level and inconsistency by two levels.

3. Participants with change in antimicrobial regimen from a broad to a narrower spectrum

No study made available sufficient and comparable information on participants who had their antimicrobial regimen changed from a broad to a narrower spectrum.

Secondary outcomes

Hospital length of stay (days)

With the exception of [Oliveira 2013](#), other trials ([Annane 2013](#); [Deliberato 2013](#); [Nobre 2008](#); [Shehabi 2014](#)) showed results favouring the procalcitonin groups, with differences in median values ranging from two days to seven days, but found no statistical significance ([Analysis 2.1](#)). However, another study ([Liu 2013](#)) showed results favouring the procalcitonin group (27.0 mean days; standard deviation (SD) = 4.9) as compared with the non-procalcitonin group (32.0 mean days; SD = 5.4), with a statistically significant difference between comparison groups (-5.00 days, 95% CI -7.24 to -2.76; $P < 0.0001$; [Analysis 2.1](#)).

ICU length of stay (days)

Four trials evaluated mean days in the ICU ([Hochreiter 2009](#); [Liu 2013](#); [Schroeder 2009](#); [Svoboda 2007](#)), resulting in a pooled effect that favoured the procalcitonin group (-2.05 days, 95% CI -3.14 to -0.97; $I^2 = 0\%$; [Analysis 2.2](#)).

Five other studies evaluated time in the ICU as median values with respective IQRs and P values ([Annane 2013](#); [Deliberato 2013](#); [Nobre 2008](#); [Oliveira 2013](#); [Shehabi 2014](#)). Four trials reported directions of effect favouring the procalcitonin groups, with differences between median values ranging from a half-day to two days, but only [Nobre 2008](#) found a statistically significant difference (0.03) between the procalcitonin group (median of 3 days; IQR 1 to 18) and the non-procalcitonin group (median of 5 days; IQR 1 to 30). [Oliveira 2013](#) found the opposite direction of effect favouring the non-procalcitonin group (median of 12 days; IQR 7 to 18) as compared with the procalcitonin group (median of 14 days; IQR 9 to 24), with no statistically significant differences ($P = 0.164$; [Analysis 2.3](#)).

Clinical severity of participant's condition

[Svoboda 2007](#) reported SOFA scores at day 28 as means and respective standard deviations, resulting in a borderline statistically non-significant difference in means of -1.40 (95% CI -2.82 to 0.02; $P = 0.5$) in favour of the procalcitonin group ([Analysis 2.4](#)).

[Annane 2013](#) also evaluated SOFA scores at days three and five but found no statistically significant differences ([Analysis 2.5](#); [Analysis 2.6](#)). [Schroeder 2009](#) analysed the SOFA_{max}, defined as the highest sequential failure assessment score, during the period

of observation but found a statistically non-significant difference between comparison groups, as shown in [Analysis 2.7](#); and [Liu 2013](#) found other non-significant difference while evaluating APACHE II ([Analysis 2.8](#)).

New infection or reinfection

After the results of [Deliberato 2013](#), [Nobre 2008](#) and [Oliveira 2013](#) were combined, the meta-analysis revealed a higher but non-significant risk of reinfection in the procalcitonin group (5/100; 5.0%) as compared with the non-procalcitonin group (3/113; 2.65%) with a risk ratio of 1.84 (95% CI 0.43 to 7.89; $I^2 = 0\%$; [Analysis 2.9](#)).

Duration of mechanical ventilation (days)

Three trials ([Annane 2013](#); [Shehabi 2014](#); [Svoboda 2007](#)) found no statistically significant differences between comparison groups, although effects favoured procalcitonin in [Annane 2013](#) and [Svoboda 2007](#) ([Analysis 2.10](#)).

Other outcomes of potential interest

After we had extracted all estimates of effects from the primary studies, we had an excess of 56 dependent variables on which to base our comparisons between procalcitonin and non-procalcitonin groups (standard care or CRP), as shown in [Analysis 3.1](#) to [Analysis 3.38](#). However, we observed significant effects in favour of procalcitonin-guided antimicrobial therapy in only eight variables related to mortality at 14 days ([Analysis 3.2](#)), in empirical antibiotic initiation ([Analysis 3.12](#); [Analysis 3.13](#)) and in an additional five ways of measuring time of antimicrobial usage ([Analysis 3.23](#); [Analysis 3.28](#); [Analysis 3.29](#); [Analysis 3.30](#); [Analysis 3.32](#)).

As a probable consequence of more rational antimicrobial usage, two study authors reported relevant reductions in costs associated with procalcitonin-guided antimicrobial therapy. [Deliberato 2013](#), for example, reported a reduction in total costs of antibiotics from USD 42,397.00 in the standard care group to USD10,608.00 in the procalcitonin-guided antimicrobial therapy group, corresponding to an approximate reduction in cost with antimicrobials of 75% ([Analysis 3.39](#)), as well as a mean cost with antibiotics plus PCT kits per participant of USD 977.40 against USD1367.64 in the non-procalcitonin group, corresponding to an approximate cost reduction of 28% ([Analysis 3.40](#)). [Schroeder 2009](#) reported an important reduction of 17% in costs of antibiotic treatment associated with procalcitonin-guided antimicrobial therapy as compared with non-procalcitonin-guided treatment ($P < 0.01$) ([Analysis 3.41](#)).

Assessment of reporting biases

We explored publication bias for mortality at longest follow-up by using the funnel plot. Visual inspection of the funnel plot ([Figure 5](#)) revealed no apparent influence (tendency) of small studies leading to more or less beneficial intervention effect estimates ([Higgins 2011](#)). Thus, we consider publication bias improbable at the present version of this systematic review.

Figure 5. Funnel plot of comparison: 1 PCT versus non-PCT (standard care or CRP: primary outcomes), outcome: 1.1 Mortality at longest follow-up.

Sensitivity analysis

Sensitivity analysis 1. Imputing missing data with mortality versus available data analysis in "Mortality at longest follow-up" outcome

We performed a sensitivity analysis to observe the effects of imputing missing data with poor outcomes in the analysis of our primary outcome of "Mortality at longest follow-up" (Higgins 2011). Our ITT analysis showed no significant differences in mortality at longest follow-up between PCT (164/613; 26.7%) and non-PCT (171/602; 28.4%) comparison groups (RR 0.98, 95% CI 0.73 to 1.32; $I^2 = 56\%$; Analysis 4.1), as in the available data analysis (RR of 0.81, 95% CI 0.65 to 1.01; $I^2 = 10\%$; Analysis 1.1).

We performed additional post hoc sensitivity analyses to test the effects of including three studies with inclusion criteria not specific

for sepsis, severe sepsis or septic shock, as previously planned in our protocol (Bouadma 2010; Jensen 2011; Layios 2012) and as shown in Sensitivity analyses 2, 3 and 4 below.

Sensitivity analysis 2. Mortality at longest follow-up in studies with inclusion criteria not specific for sepsis, severe sepsis or septic shock

Inclusion of Bouadma 2010, Jensen 2011 and Layios 2012 in a meta-analysis of 13 trials (Annane 2013; Bouadma 2010; Deliberato 2013; Dharaniyadewi 2013; Hochreiter 2009; Jensen 2011; Layios 2012; Liu 2013; Nobre 2008; Oliveira 2013; Schroeder 2009; Shehabi 2014; Svoboda 2007) revealed no significant differences in mortality at longest follow-up between PCT (435/1742; 24.9%) and non-PCT (460/1744; 26.3%) comparison groups (RR 0.92, 95% CI 0.81 to 1.05; $I^2 = 11\%$; Figure 6) as compared with included studies (RR 0.81, 95% CI 0.65 to 1.01; $I^2 = 10\%$; Analysis 1.1).

Figure 6. Sensitivity analysis including Bouadma 2010, Jensen 2011 and Layios 2012: 1 PCT versus non-PCT (standard care or CRP: primary outcomes), outcome: 1.1 Mortality at longest follow-up (Analysis 1.1).

Sensitivity analysis 3. Mortality at 28 days in studies with inclusion criteria not specific for sepsis, severe sepsis or septic shock

Inclusion of Jensen 2011 and Bouadma 2010 in a meta-analysis of six studies (Bouadma 2010; Jensen 2011; Liu 2013; Nobre 2008;

Oliveira 2013; Svoboda 2007) revealed no significant differences in mortality at 28 days between PCT (292/1071; 27.2%) and non-PCT (294/1066; 27.6%) comparison groups (RR 0.98, 95% CI 0.86 to 1.12; $I^2 = 0\%$; Figure 7) as compared with included studies (RR 0.89, 95% CI 0.61 to 1.31; four trials; $N = 316$; $I^2 = 0\%$; Analysis 1.2).

Figure 7. Sensitivity analysis including Bouadma 2010 and Jensen 2011: 1 PCT versus non-PCT (standard care or CRP: primary outcomes), outcome: 1.2 Mortality at 28 days (Analysis 1.2).

Sensitivity analysis 4. Mortality at ICU discharge in studies with inclusion criteria not specific for sepsis, severe sepsis or septic shock

Inclusion of Layios 2012 in a meta-analysis of four studies (Annane 2013; Deliberato 2013; Layios 2012; Shehabi 2014) revealed no

significant differences in mortality at ICU discharge (RR 1.04, 95% CI 0.79 to 1.38; $I^2 = 0\%$; Figure 8) compared with included studies (RR 1.03, 95% CI 0.50 to 2.11; $I^2 = 49\%$; Analysis 1.3).

Figure 8. Sensitivity analysis including Layios 2012: 1 PCT versus non-PCT (standard care or CRP: primary outcomes), outcome: 1.3 Mortality at ICU discharge (Analysis 1.3).

DISCUSSION

Summary of main results

Through our comprehensive search strategy, we retrieved 486 articles. Twelve articles met our inclusion criteria but were generated from 10 studies. This relatively small number of studies provided 59 dependent variables. Seventeen were related to primary and secondary outcomes previously planned for this systematic review. We did not omit the remaining 42 outcomes from this review because we considered them to be of potential interest to readers, including researchers and decision makers.

Primary outcomes

For mortality at 28 days, at intensive care unit (ICU) discharge, at hospital discharge and at longest follow-up, included studies were consistent in terms of showing absence of differences between procalcitonin-guided and non-procalcitonin-guided antimicrobial therapy (standard care or C-reactive protein (CRP)-guided antimicrobial therapy) ([Annane 2013](#); [Deliberato 2013](#); [Hochreiter 2009](#); [Liu 2013](#); [Nobre 2008](#); [Oliveira 2013](#); [Schroeder 2009](#); [Shehabi 2014](#); [Svoboda 2007](#)), with the exception of [Dharaniyadewi 2013](#).

Three out of four trials ([Hochreiter 2009](#); [Liu 2013](#); [Schroeder 2009](#)) showed that duration of antimicrobial therapy was reduced by more than one day, but one study ([Oliveira 2013](#)) showed non-significant statistical differences that favoured CRP-guided antimicrobial therapy. Additionally, [Deliberato 2013](#) noted a statistically significant reduction of four days in duration of antimicrobial therapy associated with the procalcitonin group, measured as median values; however, [Annane 2013](#) did not observe such a significant reduction in the time it took to receive antimicrobial therapy.

Secondary outcomes

[Liu 2013](#) showed a statistically significant reduction of five days of stay in the hospital in the procalcitonin group. [Annane 2013](#), [Deliberato 2013](#), [Nobre 2008](#), [Oliveira 2013](#) and [Shehabi 2014](#) reported length of hospital stay as median values. Four of these studies showed statistically non-significant reductions in favour of procalcitonin groups, which varied from two to six days of stay in the hospital ([Annane 2013](#); [Deliberato 2013](#); [Nobre 2008](#); [Shehabi 2014](#)).

Four studies reported more optimistic results for ICU length of stay, with an approximate mean difference of two days in favour of the procalcitonin groups ([Hochreiter 2009](#); [Liu 2013](#); [Schroeder 2009](#); [Svoboda 2007](#)), but [Oliveira 2013](#) observed non-significant results. [Annane 2013](#), [Deliberato 2013](#), [Nobre 2008](#), [Oliveira 2013](#) and [Shehabi 2014](#) reported results as median values, but only [Nobre 2008](#) noted a significant difference of two days in favour of the procalcitonin group.

Although participants in some included studies showed a propensity for a shorter stay in both hospital and ICU, all studies that evaluated the clinical severity of the participant's condition ([Annane 2013](#); [Liu 2013](#); [Schroeder 2009](#); [Svoboda 2007](#)), reinfection ([Deliberato 2013](#); [Nobre 2008](#); [Oliveira 2013](#)) and duration of mechanical ventilation ([Annane 2013](#); [Shehabi 2014](#); [Svoboda 2007](#)) showed no relevant effect associated with procalcitonin-guided antimicrobial therapy. However, the higher

proportion of reinfection among procalcitonin groups is supposed to be caused by reduced antibiotic exposure.

Other outcomes of potential interest for the user

Investigators reported significant effects in favour of procalcitonin-guided antimicrobial therapy for other outcomes not planned for this systematic review, specifically, mortality at day 14 ([Dharaniyadewi 2013](#)) and empirical antibiotic initiation ([Dharaniyadewi 2013](#)) and five additional ways of measuring the time receiving antimicrobial treatment ([Nobre 2008](#); [Oliveira 2013](#); [Shehabi 2014](#)). More promising findings were the cost reductions associated with procalcitonin-guided antimicrobial therapy, which varied from 17% to 75%, depending on the method of cost evaluation applied ([Deliberato 2013](#); [Schroeder 2009](#)). However, all of these results are limited and should be read with caution.

Overall completeness and applicability of evidence

Evidence presented in this systematic review shows absence of a clear effect of procalcitonin-guided antimicrobial therapy in minimizing mortality, reinfection, clinical severity or mechanical ventilation of patients with sepsis, severe sepsis or septic shock. However, procalcitonin evaluation has relevant potential for reducing the duration of antimicrobial therapy, as well as patient stay in both hospital and ICU.

The reader should consider the possibility of insufficient sample power for all outcomes because of the low number of included studies, which totalled at most 1156 participants for one outcome in primary studies: mortality at longest follow-up. Otherwise, a post hoc sensitivity analysis performed to test the effects of including three studies with inclusion criteria not specific for sepsis, severe sepsis or septic shock ([Bouadma 2010](#); [Jensen 2011](#); [Layios 2012](#)) had no significant effect on measures of mortality.

It is important to consider that, although we found low mortality rates of around 20% in both comparison groups, all studies had included high percentages of participants with severe and/or septic shock, with the exception of [Hochreiter 2009](#) and [Liu 2013](#), which did not specify these proportions.

Although it was not previously planned as a primary or secondary outcome, our analysis revealed promising effects of procalcitonin-guided antimicrobial therapy in reducing costs as a probable consequence of reducing time on the antimicrobial regimen, but such findings should be confirmed/refuted by future experimental or observational studies in which investigators perform economic analysis.

Another important issue involves the diagnostic accuracy of procalcitonin for septic conditions and their prognosis. Despite its limitations, no better biomarker for sepsis and its prognosis is known ([García de Guadiana-Romualdo 2015](#); [Garnacho-Montero 2014](#); [Hoeboer 2015](#); [Leli 2014](#); [Liu 2015](#); [Nargis 2014](#)).

Quality of the evidence

According to [Summary of findings for the main comparison](#), we considered the evidence to be of low quality for mortality at longest follow-up, mortality at 28 days and mortality at ICU discharge, and of moderate quality for mortality at hospital discharge, with no significant effect of procalcitonin-guided antimicrobial therapy, even when this approach was compared with standard care.

Although we included 10 studies in this systematic review, only the outcome of "mortality at longest follow-up" was reported by 10 studies, for which trial sequential analysis showed an actual sample size corresponding to approximately 40% of the required information size (1156 of 2853 participants). Moreover, although four studies reported relevant reduction in the time of antimicrobial therapy, these studies were associated with serious risk of bias, resulting in evidence of very low quality for this specific outcome.

Visual inspection of the funnel plot revealed no asymmetry, suggesting absence of publication bias. The possibility that investigators have not made their studies available for reasons of absence of effect is improbable because most of the studies included in this systematic review showed absence of differences for several other outcomes, including primary and secondary outcomes. Even so, we should not dismiss the possibility that investigators may not make available studies showing negative effects of procalcitonin-guided antimicrobial therapy because studies with positive results are more likely to be published (Kicinski 2013).

One of the most important points to be stressed to the reader and the scientific community is that both the precision of our effect estimates and the quality of the evidence were affected by the large number of dependent variables that have been evaluated in studies published to this point. In this systematic review, we could find 59 outcomes in 10 studies. Thus, higher-quality evidence will certainly be achieved if researchers concentrate their efforts on analysis of common and clinically relevant outcomes. Upon thinking of the large divergence of outcomes assessed in these studies, we provided estimates of effects for all outcomes reported in the primary studies included in this review.

Potential biases in the review process

Besides using a highly sensitive strategy in our search for studies, we applied no language restrictions, resulting in the inclusion of a publication written in Chinese (Liu 2013). After we reran the search (October 2016), we retrieved three additional studies of interest and included them in the list of [Studies awaiting classification](#). We will incorporate these studies into our formal review findings during the review update; these findings will contribute 94.4% (2695 participants) of the required information size of 2853 participants, according to the trial sequential analysis. Although it is improbable that these studies will change estimated effects on mortality, they may change other relevant outcomes, especially hospital and ICU length of stay, as well as time on antimicrobial therapy and mechanical ventilation.

We could not minimize during the review process a source of bias that was precisely related to the evaluation of risk of bias for some studies because we had no success in obtaining additional information from the authors of four primary studies (Dharaniyadewi 2013; Hochreiter 2009; Liu 2013; Schroeder 2009). One of these studies is available only as an extended abstract (Dharaniyadewi 2013).

We included mortality at longest follow-up as one additional primary outcome because absence of evidence on mortality often results from insufficient power, as well as from clinical and methodological heterogeneity between studies. However, we believe such an inclusion does not introduce potential bias into the review process because no substitution of outcomes occurred,

and evidence of absence of effect could be reinforced by this new outcome.

Agreements and disagreements with other studies or reviews

In a narrative review with some elements of a systematic review (systematic search across relevant databases), Mann 2011 focused analysis on the accuracy of procalcitonin for diagnosing sepsis in critically ill burn patients. After analysing 14 observational studies and five systematic reviews, these review authors supported the discriminatory capacity of procalcitonin as an important tool to be combined with the clinical diagnosis of sepsis. Another narrative review by Schuetz 2013 not only supports procalcitonin evaluation as a valuable diagnostic tool for respiratory infection and sepsis but also suggests desired repercussions of procalcitonin evaluation in reducing the time it takes to receive antimicrobial therapy, without affecting mortality. Besides narrative reviews, the medical literature already includes several systematic reviews conducted to investigate the potential causal relationship between procalcitonin monitoring and relevant outcomes such as mortality, but these review authors included studies that used different inclusion criteria (Kopterides 2010; Prkno 2013; Schuetz 2011). These three systematic reviews yielded a total of 14 included randomized controlled trials (RCTs).

Two systematic reviews analysed studies consisting of critically ill adult and neonatal participants (Kopterides 2010), as well as adult participants from primary care, emergency department and ICU (Schuetz 2011), but review authors were not strictly interested in patients with sepsis, severe sepsis and/or septic shock at study entry, according to our inclusion criteria. Another systematic review by Prkno 2013 included RCTs and observational studies that evaluated adult participants with severe sepsis. Among the RCTs analysed by Prkno 2013, we noted the inclusion of Jensen 2011, which we did not consider in our systematic review. We clearly justified the exclusion of Jensen 2011 from our systematic review on the basis of broad inclusion criteria for patients admitted to the ICU, also without a strict interest in sepsis, severe sepsis or septic shock, which was similar to the approach of Kopterides 2010 and Schuetz 2011. Another difference from other systematic reviews was our inclusion of three additional studies that met our inclusion criteria (Liu 2013; Oliveira 2013; Shehabi 2014). Even under such methodological divergences, Prkno 2013, Kopterides 2010 and Schuetz 2011 provided conclusions consistent with those of our systematic review because they noted the same general evidence of absence of effect for mortality and shorter time receiving antibiotic treatment that we had observed in procalcitonin-guided antimicrobial therapy as compared with non-procalcitonin-guided treatment. However, as opposed to Kopterides 2010 and Prkno 2013, our systematic review shows a probable reduction in the time patients stay in the hospital and in the ICU, which remains to be adequately proven.

Besides the above-mentioned general agreement among systematic reviews, other updated and important observational and health economic studies have reported shorter hospital stay (Kip 2015) and less time receiving antibiotic therapy (Hohn 2013; Hohn 2015; Kip 2015; Maseda 2015), with a probable consequence of relevant cost reductions, as reported specifically by Kip 2015.

Finally, it is important to consider that, since 2012, one of the main existing guidelines for dealing with severe sepsis and septic shock

(Dellinger 2013) has included recommending procalcitonin to support clinicians while they decide whether or not to discontinue empirical antimicrobial therapy for patients with septic conditions. However, Dellinger 2013 assumes low quality of available evidence for this recommendation.

AUTHORS' CONCLUSIONS

Implications for practice

Evidence of low to moderate quality does not support the use of procalcitonin-guided antimicrobial therapy to minimize mortality, reinfection, clinical severity, mechanical ventilation, or duration of antimicrobial therapy of patients with sepsis, severe sepsis or septic shock. However, the reader should consider the possibility of insufficient sample power for all outcomes.

Implications for research

The findings of this systematic review suggest promising effects of procalcitonin-guided antimicrobial therapy in reducing the stay of patients in both the hospital and the ICU, which deserve better

confirmation from RCTs. Next trials should include an additional 1697 participants to confirm possible superiority of procalcitonin for mortality at longest follow-up as compared with control. The possible reduction in costs (as a probable consequence of reduced time on the antimicrobial regimen) should also be confirmed/refuted by future studies in which investigators perform cost analyses.

ACKNOWLEDGEMENTS

We would like to thank the Cochrane Anaesthesia, Critical and Emergency Care Group (ACE) for its support, and Arash Afshari (Content Editor), Nathan Pace (Statistical Editor) and Arturo J Martí-Carvajal, Djillali Annane and James Washam (Peer Reviewers) for help and editorial advice provided during preparation of the protocol for this systematic review (Silva 2014); as well as Arash Afshari (Content Editor), Jing Xie (Statistical Editor), James Walsham and David T Huang (Peer Reviewers) and Brian Stafford (Consumer Referee) for help and editorial advice provided during preparation of this systematic review, and Gustavo Porfírio (Brazilian Cochrane Centre) for assistance in the search for studies.

REFERENCES

References to studies included in this review

Annane 2013 {published data only}

Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. *BMJ Open* 2013;**3**(2):e002186. [PUBMED: 23418298]

Deliberato 2013 {published data only}

Deliberato RO, Marra AR, Sanches PR, Martino MD, Ferreira CE, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. *Diagnostic Microbiology and Infectious Disease* 2013;**76**(3):266-71. [PUBMED: 23711530]

Dharaniyadewi 2013 {published data only}

Dharaniyadewi D, Lie KC, Sukmana N, Rumende CM. Effect of semi-quantitative procalcitonin assay on the adequacy of empirical antibiotics and mortality in septic patients. *Critical Care* 2013;**17**:10. [DOI: [10.1186/cc12915](https://doi.org/10.1186/cc12915)]

Hochreiter 2009 {published data only}

Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. *Critical Care (London, England)* 2009;**13**(3):R83. [PUBMED: 19493352]

Liu 2013 {published data only}

Liu BH, Li HF, Lei Y, Zhao SX, Sun ML. Clinical significance of dynamic monitoring of procalcitonin in guiding the use of antibiotics in patients with sepsis in ICU [动态监测降钙素原对 ICU 脓毒症患者 抗菌药物使用的临床意义]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2013;**25**(11):690-3. [PUBMED: 24225216]

Nobre 2008 {published data only}

Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. *American Journal of Respiratory and Critical Care Medicine* 2008;**177**(5):498-505. [PUBMED: 18096708]

Oliveira 2013 {published data only}

Oliveira CF, Botoni FA, Oliveira CA, Pereira HAC, Padua M, Nobre V. The usefulness of C-reactive protein (CRP) compared to procalcitonin (PCT) to reduce antibiotic exposure in critically ill patients with sepsis: a pilot study. *Intensive Care Medicine*. 2011; Vol. 37:S200. [CN-01035397]

* Oliveira CF, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. *Critical Care Medicine* 2013;**41**(10):2336-43. [PUBMED: 23921272]

Schroeder 2009 {published data only}

Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces

length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. *Langenbeck's Archives of Surgery* 2009;**394**(2):221-6. [PUBMED: 19034493]

Shehabi 2014 {published data only}

Shehabi Y, Rachakonda KS, Bailey MJ, Peake S. Reply. No significant reduction in antibiotic treatment using a procalcitonin algorithm with low cutoff value in the intensive care unit?. *American Journal of Respiratory and Critical Care Medicine* 2015;**191**(7):859-60.

Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. *American Journal of Respiratory and Critical Care Medicine* 2014;**190**(10):1102-10. [PUBMED: 25295709]

Svoboda 2007 {published data only}

Svoboda P, Kantorová I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?. *Hepatogastroenterology* 2007;**54**(74):359-63. [PUBMED: 17523274]

References to studies excluded from this review

Bodmann 2016 {published data only}

Bodmann KF, Schenker M, Heinlein W, Wilke MH. Procalcitonin as a tool for the assessment of successful therapy of severe sepsis: an analysis using clinical routine data [Eine Untersuchung mit klinischen Routinedaten]. *Medizinische Klinik, Intensivmedizin und Notfallmedizin* 2016;**Epub ahead of print**:1-8. [PUBMED: 27376540]

Bouadma 2010 {published data only}

Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *The Lancet* 2010;**375**(9713):463-74. [PUBMED: 20097417]

Bréchet 2015 {published data only}

Bréchet N, Hékimian G, Chastre J, Luyt CE. Procalcitonin to guide antibiotic therapy in the ICU. *International Journal of Antimicrobial Agents* 2015;**46**(Suppl 1):S19-24. [PUBMED: 26607343]

Harrison 2015 {published data only}

Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? Infection control and hospital epidemiology. *Infection Control and Hospital Epidemiology* 2015;**36**(3):265-72. [DOI: [10.1017/ice.2014.60](https://doi.org/10.1017/ice.2014.60)]

Jensen 2011 {published data only}

Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, et al. Kidney failure related to broad-spectrum

antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. *BMJ Open* 2012;**2**(2):e000635. [PUBMED: 22411933]

* Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. *Critical Care Medicine* 2011;**39**(9):2048-58. [PUBMED: 21572328]

Jensen JU, Lundgren B, Hein L, Mohr T, Petersen PL, Andersen LH, et al. The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. *BMC Infectious Diseases* 2008;**8**:91. [PUBMED: 18620598]

Johansen ME, Jensen JU, Bestle MH, Hein L, Lauritsen AØ, Tousi H, et al. The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. *Public Library of Science PLoS ONE* 2013;**8**(11):e81477. [PUBMED: 24312305]

Kiehntopf 2011 {published data only}

Kiehntopf M, Hutagalung R, Bloos F, Oppert M, Grundling M, Weiler N, et al. Prognostic impact of procalcitonin in severe sepsis and septic shock: results of the VISEP study. *Infection* 2011;**39**(Suppl 2):S114-5. [CENTRAL: CN-01005880]

Kip 2015 {published data only}

Kip MM, Kusters R, IJzerman MJ, Steuten LM. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. *Journal of Medical Economics* 2015;**18**(11):944-53. [PUBMED: 26105574]

Kolici 2013 {published data only}

Kolici N, Tushe E, Dedej G, Kolici E, Foto E. Role of semi-quantitative procalcitonin test kit versus CRP to "rule out" neonatal sepsis. *Intensive Care Medicine* 2013;**41**(1):S189-90. [CENTRAL: CN-01060306; DOI: [10.1007/s00134-013-2950-8](https://doi.org/10.1007/s00134-013-2950-8)]

Kopterides 2010 {published data only}

Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. *Critical Care Medicine* 2010;**38**(11):2229-41. [PUBMED: 20729729]

Layios 2012 {published data only}

Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. *Critical Care Medicine* 2012;**40**(8):2304-9. [PUBMED: 22809906]

Lima 2016 {published data only}

Lima SS, Nobre V, de Castro Romanelli RM, Clemente WT, da Silva Bittencourt HN, Melo AC, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in

febrile neutropenia: a randomized controlled trial. *Annals of Hematology* 2016;**95**(7):1169-76. [PUBMED: 27118539]

Mann 2011 {published data only}

Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. *Burns* 2011;**37**(4):549-58. [PUBMED: 20537467]

Pantelidou 2015 {published data only}

Pantelidou IM, Giamarellos-Bourboulis EJ. Can procalcitonin monitoring reduce the length of antibiotic treatment in bloodstream infections?. *International Journal of Antimicrobial Agents* 2015;**48**(Suppl 1):S10-2. [PUBMED: 26686272]

Prkno 2013 {published data only}

Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock: a systematic review and meta-analysis. *Critical Care (London, England)* 2013;**17**(6):R291. [PUBMED: 24330744]

Sandifer 2012 {published data only}

Sandifer JP, Jones AE. Can procalcitonin levels guide antibiotic therapy in bacterial infections and reduce antibiotic over consumption without having a negative effect on clinical outcomes?. *Annals of Emergency Medicine* 2012;**60**(3):370-1. [PUBMED: 22305332]

Schuetz 2011 {published data only}

Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. *Archives of Internal Medicine* 2011;**171**(15):1322-31. [PUBMED: 21824946]

Schuetz 2013 {published data only}

Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. *Current Opinion in Critical Care* 2013;**19**(5):453-60. [PUBMED: 23817026]

Soni 2013 {published data only}

Soni NJ, Samson DJ, Galaydick JL, Vats V, Huang ES, Aronson N, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. *Journal of Hospital Medicine* 2013;**8**(9):530-40. [PUBMED: 23955852]

Stocker 2010a {published data only}

Stocker M, Hop WC, van Rossum AM. Neonatal Procalcitonin Intervention Study (NeoPInS): effect of procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: a multi-centre randomized superiority and non-inferiority intervention study. *BioMed Central Pediatrics* 2010;**10**:89. [PUBMED: 21143869]

Stocker 2010b {published data only}

Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis:

prospective randomized intervention trial. *Neonatology* 2010;**97**(2):165-74. [PUBMED: 19776651]

Ternhag 2010 {published data only}

Ternhag A, Cars O, Norman C, Struwe J. Antibiotics or not - procalcitonin can guide therapeutic choices. At least at the emergency department for adults with lower respiratory tract infection [Antibiotika eller inte - procalcitonin kan vägleda behandlingsval]. *Lakartidningen* 2010;**107**(15):98. [MEDLINE: 20464915]

Westwood 2015 {published data only}

Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. *Health Technology Assessment (Winchester, England)* 2015;**19**(96):v-xxv, 1-236. [PUBMED: 26569153]

References to studies awaiting assessment

Bloos 2016 {published data only}

Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. *JAMA Internal Medicine* 2016;**176**(9):1266-76. [PUBMED: 27428731]

de Jong 2016 {published data only}

Assink-de Jong E, de Lange DW, van Oers JA, Nijsten MW, Twisk JW, Beishuizen A. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients - calculated sample size: 1816 patients. *BioMed Central Infectious Diseases* 2013;**13**:178. [PUBMED: 23590389]

* de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *The Lancet Infectious Diseases* 2016;**16**(7):819-27. [PUBMED: 26947523]

Najafi 2015 {published data only}

Najafi A, Khodadadian A, Sanatkar M, Moharari RS, Etezadi F, Ahmadi A, et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. *Acta Medica Iranica* 2015;**53**(9):562-7. [PUBMED: 26553084]

Additional references

ACCP/SCCM Consensus Conference Committee 1992

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies

in sepsis. *Critical Care Medicine* 1992;**20**(6):864-74. [PUBMED: 1597042]

Adhikari 2010

Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. *The Lancet* 2010;**376**(9749):1339-46. [PUBMED: 20934212]

Assunção 2010

Assunção M, Akamine N, Cardoso GS, Mello PV, Teles JM, Nunes AL, et al. Survey on physicians' knowledge of sepsis: do they recognize it promptly?. *Journal of Critical Care* 2010;**25**(4):545-52. [PUBMED: 20646902]

Azevedo 2012

Azevedo JR, Torres OJ, Czeckzo NG, Tuon FF, Nassif PA, Souza GD. Procalcitonin as a prognostic biomarker of severe sepsis and septic shock. *Revista do Colégio Brasileiro de Cirurgias* 2012;**39**(6):456-61. [PUBMED: 23348640]

Becker 2008

Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. *Critical Care Medicine* 2008;**36**(3):941-52. [PUBMED: 18431284]

Bone 1992

Bone RC, Balk RA, Cerra FB. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992;**101**(6):1644-55. [PUBMED: 1303622]

Bone 2009

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 2009;**136**(5 Suppl):e28. [PUBMED: 20162763]

Brok 2009

Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. *International Journal of Epidemiology* 2009;**38**(1):287-98. [PUBMED: 18824466]

Chalupa 2011

Chalupa P, Beran O, Herwald H, Kaspříková N, Holub M. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. *Infection* 2011;**39**(5):411-7. [PUBMED: 21720792]

Christensen 2006

Christensen PM, Kristiansen IS. Number-needed-to-treat (NNT) - needs treatment with care. *Basic & Clinical Pharmacology & Toxicology* 2006;**99**(1):12-6. [PUBMED: 16867164]

Cuthbertson 2013

Cuthbertson BH, Elders A, Hall S, Taylor J, MacLennan G, McKirdy F, et al. Mortality and quality of life in the five years after severe sepsis. *Critical Care* 2013;**17**(2):R70. [PUBMED: 23587132]

Dellinger 2013

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock 2012. *Intensive Care Medicine* 2013;**39**(2):165-228. [PUBMED: 23361625]

García de Guadiana-Romualdo 2015

García de Guadiana-Romualdo LM, Rebollo-Acebes S, Esteban-Torrella P, Jiménez-Sánchez R, Hernando-Holgado A, Ortín-Freire A, et al. Prognostic value of lipopolysaccharide binding protein and procalcitonin in patients with severe sepsis and septic shock admitted to intensive care [Valor pronóstico de la proteína fijadora de lipopolisácaridos y la procalcitonina en pacientes con sepsis grave y shock séptico ingresados en una unidad de cuidados intensivos]. *Medicina Intensiva* 2015;**39**(4):207-12. [PUBMED: 24953001]

Garnacho-Montero 2014

Garnacho-Montero J, Huici-Moreno MJ, Gutiérrez-Pizarra A, López I, Márquez-Vácaro JA, Macher H, et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. *Critical Care* 2014;**18**(3):R116. [PUBMED: 24903083]

Gendrel 1999

Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. *The Pediatric Infectious Disease Journal* 1999;**18**(10):875-81. [PUBMED: 10530583]

GRADEpro 2014 [Computer program]

McMaster University. GRADEpro. McMaster University, 2014.

Guyatt 2008

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians. *BMJ* 2008;**336**(7651):995-8. [PUBMED: 18456631]

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.

Hingorani 2013

Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. *BMJ* 2013;**346**:e5793. [PUBMED: 23386361]

Hoeboer 2015

Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. *Clinical Microbiology and Infection* 2015;**21**(5):474-81. [PUBMED: 25726038]

Hohn 2013

Hohn A, Schroeder S, Gehrt A, Bernhardt K, Bein B, Wegscheider K, et al. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. *BioMed Central Infectious Diseases* 2013;**13**:158. [PUBMED: 23547790]

Hohn 2015

Hohn A, Heising B, Hertel S, Baumgarten G, Hochreiter M, Schroeder S. Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis. *Infection* 2015;**43**(4):405-12. [PUBMED: 25588968]

Hosein 2011

Hosein S, Udy AA, Lipman J. Physiological changes in the critically ill patient with sepsis. *Current Pharmaceutical Biotechnology* 2011;**12**(12):1991-5. [PUBMED: 21554219]

Jawad 2012

Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. *Journal of Global Health* 2012;**2**(1):10404. [PUBMED: 23198133]

Karlsson 2009

Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettilä V, Finnsepsis Study Group. Long-term outcome and quality-adjusted life years after severe sepsis. *Critical Care Medicine* 2009;**37**(4):1268-74. [PUBMED: 19242321]

Kenzaka 2012

Kenzaka T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, et al. Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis. *International Journal of General Medicine* 2012;**5**:483-8. [PUBMED: 22701089]

Kicinski 2013

Kicinski M. Publication bias in recent meta-analyses. *PLoS ONE* 2013;**8**(11):e81823. [DOI: [10.1371/journal.pone.0081823](https://doi.org/10.1371/journal.pone.0081823)]

Klein 2012

Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria. *Intensive Care Medicine* 2012;**38**(5):811-9. [PUBMED: 22476449]

Kuehn 2013

Kuehn BM. Guideline promotes early, aggressive sepsis treatment to boost survival. *JAMA* 2013;**309**(10):969-70. [PUBMED: 23483148]

Kumar 2010

Kumar A. Early antimicrobial therapy in severe sepsis and septic shock. *Current Infectious Disease Reports* 2010;**12**(5):336-44. [PUBMED: 21308515]

Lagu 2012

Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. *Critical Care Medicine* 2012;**40**(3):754-61. [PUBMED: 21963582]

Leli 2014

Leli C, Cardaccia A, Ferranti M, Cesarini A, D'Alò F, Ferri C, et al. Procalcitonin better than C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in predicting DNAemia in patients with sepsis. *Scandinavian Journal of Infectious Diseases* 2014;**46**(11):745-52. [PUBMED: 25195647]

Levy 2003

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Intensive Care Medicine* 2003;**29**(4):530-8. [PUBMED: 12664219]

Lichtenstern 2012

Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA. Predictors of survival in sepsis: what is the best inflammatory marker to measure?. *Current Opinion in Infectious Diseases* 2012;**25**(3):328-36. [PUBMED: 22421751]

Liu 2015

Liu D, Su L, Han G, Yan P, Xie L. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. *PLoS ONE* 2015;**10**(6):e0129450. [PUBMED: 26076027]

Machado 2013

Machado FR, Salomão R, Rigato O, Ferreira EM, Schettino G, Mohovic T, et al. Late recognition and illness severity are determinants of early death in severe septic patients. *Clinics (Sao Paulo)* 2013;**68**(5):586-91. [PUBMED: 23778420]

Maravić-Stojković 2011

Maravić-Stojković V, Lausević-Vuk L, Jović M, Ranković A, Borzanović M, Marinković J. Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. *Srpski Arhiv za Celokupno Lekarstvo* 2011;**139**(11-12):736-42. [PUBMED: 22338468]

Maseda 2015

Maseda E, Suarez-de-la-Rica A, Anillo V, Tamayo E, García-Bernedo CA, Ramasco F, et al. Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: a multicenter retrospective study. *Journal of Critical Care* 2015;**30**(3):537-42. [PUBMED: 25600574]

Matthaiou 2012

Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy

algorithms in adult critically ill patients. *Intensive Care Medicine* 2012;**38**(6):940-9. [PUBMED: 22538461]

McCann 2012

McCann FJ, Chapman SJ, Yu WC, Maskell NA, Davies RJ, Lee YC. Ability of procalcitonin to discriminate infection from non-infective inflammation using two pleural disease settings. *PLoS ONE* 2012;**7**(12):e49894. [PUBMED: 23251353]

Morgenthaler 2003

Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. *Hormone and Metabolic Research* 2003;**35**(5):290-5. [PUBMED: 12915998]

Nargis 2014

Nargis W, Ibrahim M, Ahamed BU. Procalcitonin versus C-reactive protein: usefulness as biomarker of sepsis in ICU patient. *International Journal of Critical Illness and Injury Science* 2014;**4**(3):195-9. [PUBMED: 25337480]

Redl 2000

Redl H, Schlag G, Tögel E, Assicot M, Bohuon C. Procalcitonin release patterns in a baboon model of trauma and sepsis: relationship to cytokines and neopterin. *Critical Care Medicine* 2000;**28**(11):3659-63. [PUBMED: 11098970]

RevMan 5.3 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Rivers 2012

Rivers EP, Katranji M, Jaehne KA, Brown S, Abou Dagher G, Cannon C, et al. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. *Minerva Anestesiologica* 2012;**78**(6):712-24. [PUBMED: 22447123]

Rodger 2012

Rodger M, Ramsay T, Fergusson D. Diagnostic randomized controlled trials: the final frontier. *Trials Journal* 2012;**13**:137. [PUBMED: 22897974]

Salluh 2011

Salluh JI, Lisboa T. C-reactive protein in community-acquired sepsis: you can teach new tricks to an old dog. *Critical Care* 2011;**15**(5):186. [PUBMED: 21955725]

Salvo 1995

Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, et al. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. *Intensive Care Medicine* 1995;**Suppl 2**:S244-9. [PUBMED: 8636531]

Schuetz 2012

Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database of Systematic Reviews* 2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2]

Shaikh 2011

Shaikh N, Evron J, Leeftang MM. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children. *Cochrane Database of Systematic Reviews* 2011, Issue 6. [DOI: [10.1002/14651858.CD009185](https://doi.org/10.1002/14651858.CD009185)]

Silva 2004

Silva E, Pedro Mde A, Sogayar AC, Mohovic T, Silva CL, Janiszewski M, et al. Brazilian Sepsis Epidemiological Study (BASES study). *Critical Care* 2004;**8**(4):R251-60. [DOI: [10.1186/cc2892](https://doi.org/10.1186/cc2892); PUBMED: 15312226]

Suresh 2013

Suresh G, Soll R. The diagnostic accuracy of C-reactive protein and procalcitonin for neonatal sepsis (registered Cochrane title). <http://www.archie.cochrane.org/search.jsp> (accessed 31 January 2014).

Tang 2007

Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. *The Lancet Infectious Diseases* 2007;**7**(3):210-7. [PUBMED: 17317602]

Tang 2009

Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. *Infection* 2009;**37**(6):497-507. [PUBMED: 19826761]

Tasdelen 2010

Tasdelen Fisgin N, Aliyazicioglu Y, Tanyel E, Coban AY, Ulger F, Zivalioglu M, et al. The value of neopterin and procalcitonin in patients with sepsis. *Southern Medical Journal* 2010;**103**(3):216-9. [PUBMED: 20134373]

te Witt 2012

te Witt R, Hassing RJ, Petit PP, van Belkum A, van Genderen PJ. Procalcitonin and neopterin levels do not accurately distinguish bacterial from viral infections in ill-returned travellers with fever. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2012;**106**(4):264-6. [PUBMED: 22357400]

Tsalik 2012

Tsalik EL, Jaggars LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, et al. Discriminative value of

inflammatory biomarkers for suspected sepsis. *Journal of Emergency Medicine* 2012;**43**(1):97-106. [PUBMED: 22056545]

Uusitalo-Seppälä 2011

Uusitalo-Seppälä R, Koskinen P, Leino A, Peuravuori H, Vahlberg T, Rintala EM. Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6. *Scandinavian Journal of Infectious Diseases* 2011;**43**(11-12):883-90. [PUBMED: 21892899]

Vaughan-Sarrazin 2011

Vaughan-Sarrazin MS, Bayman L, Cullen JJ. Costs of postoperative sepsis: the business case for quality improvement to reduce postoperative sepsis in Veterans Affairs hospitals. *Archives of Surgery* 2011;**146**(8):944-51. [PUBMED: 21502443]

Wacker 2013

Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. *The Lancet Infectious Diseases* 2013;**13**(5):426-35. [PUBMED: 23375419]

Wetterslev 2008

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *Journal of Clinical Epidemiology* 2008;**61**(1):64-75. [PUBMED: 18083463]

Zannoni 2012

Zannoni A, Giunti M, Bernardini C, Gentilini F, Zaniboni A, Bacci ML, et al. Procalcitonin gene expression after LPS stimulation in the porcine animal model. *Research in Veterinary Science* 2012;**93**(2):921-7. [PUBMED: 22001598]

References to other published versions of this review

Silva 2014

Silva BNG, Andriolo RB, Salomão R, Atallah ÁN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adult patients with sepsis, severe sepsis and septic shock. *Cochrane Database of Systematic Reviews* 2014, Issue 2. [DOI: [10.1002/14651858.CD010959](https://doi.org/10.1002/14651858.CD010959)]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Annane 2013

Methods	Study design: multi-centre, parallel, randomized, single-blind, controlled trial Setting: 8 ICUs in France
Participants	Inclusion criteria: all ICU patients with severe or septic shock presenting systemic inflammatory response syndrome, acute dysfunction of at least 1 organ, absence of indisputable clinical infection and negative microbial cultures, all of them for < 48 hours

Annane 2013 (Continued)

Exclusion criteria: pregnancy, burns over $\geq 15\%$ of body surface area, trauma, outpatient or inpatient cardiac arrest, post-orthopaedic surgery status drug-related neutropenia, withdrawal of life-supportive therapies or a decision to withhold them, indisputable clinical infection or antibiotic exposure ≥ 48 hours during the time shortly before ICU admission

Interventions

Group 1 (N = 31): Both initiation and discontinuation of antibiotics were guided by a PCT-based algorithm applied at 6 hours and on day 3 and day 5 post randomization. Antibiotic therapy was not to be started or was to be halted when PCT was $< 0.25 \mu\text{g/L}$, was strongly discouraged when PCT was ≥ 0.25 to $< 0.5 \mu\text{g/L}$, was recommended when PCT was ≥ 0.5 to $< 5 \mu\text{g/L}$ and was strongly recommended when PCT was $\geq 5 \mu\text{g/L}$. For participants enrolled in the 48-hour postoperative period, respective PCT cut-offs were $< 4 \mu\text{g/L}$, ≥ 4 to $< 9 \mu\text{g/L}$ and $\geq 9 \mu\text{g/L}$. Investigators were strongly asked not to over-rule the algorithm every day up to study day 5.

Group 2 (N = 31): In the control arm, the decision to start or stop antibiotic therapy was made at the discretion of the participant's physician, without knowledge of the participant's PCT concentrations.

Outcomes

1. Proportion of antibiotic-treated participants at 6 hours
2. Proportion of antibiotic-treated participants at day 3
3. Proportion of antibiotic-treated participants at day 5
4. Time on antibiotic therapy (median days and interquartile rates)
5. Participants who had started antibiotics at day 1 post randomization
6. Mortality at day 5 post randomization
7. ICU mortality
8. In-hospital mortality
9. Mortality at hospital discharge
10. SOFA score at day 3
11. SOFA score at day 5
12. ICU length of stay
13. Hospital length of stay
14. Non-survivors considered as being antibiotic-free
15. Non-survivors considered as being treated with antibiotic
16. All participants with last information carried over for non-survivors
17. Days on antibiotic therapy
18. Antibiotic therapy-free days
19. Days on mechanical ventilation
20. Acquired infections at day 3
21. Acquired infections at day 5
22. Acquired infections at day 3
23. Acquired infections at any time post randomization
24. Nasal swabs (methicillin-resistant *Staphylococcus aureus*)
25. Rectal swabs (extended-spectrum β -lactamase-resistant)
26. Rectal swabs (*Enterobacter klebsiella*)

Conflicts of interest and/or funding

None detected

Notes

Sample size: Study authors estimated that on day 5, $\sim 85\%$ of control participants would be taking antibiotics. Thus, they calculated that 57 participants in each arm would be needed to detect in a 2-sided test with an 80% probability and a 0.05 type I error a 25% absolute reduction in the proportion of antibiotic-treated participants on day 5. They also estimated that 20% of participants would eventually be withdrawn from the study after showing indisputable infection. Thus, 140 participants in total (70 in each arm) would be needed.

PCT measures: PCT levels were measured with the BRAHMS PCT-sensitive KRYPTOR assay

Annane 2013 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomized in a 1:1 ratio according to a computer-generated list and were stratified by centre and according to whether or not participants underwent surgery in the past 48 hours, using permutation blocks.
Allocation concealment (selection bias)	Low risk	Randomization was centralized through a secured website and was performed by an independent statistician. The sizes of the strata remained unknown to investigators.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Masking of antibiotic therapy was not feasible in this study, but In the control arm, participants, physicians, nurses, investigators, study co-ordinators, the statistician and the sponsor remained blinded to PCT levels throughout the study.
Blinding of outcome assessment (detection bias) All outcomes	High risk	In the control arm, participants, physicians, nurses, investigators, study co-ordinators, the statistician and the sponsor remained blinded to PCT levels throughout the study.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Although 6.45% (4/62) of all participants withdrew after randomization (PCT, n = 1; non-PCT, n = 3), study authors made available a clear flow of participants, permitting both intention-to-treat and available case analyses.
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes were analysed and were previously planned in the clinicaltrials.gov study (NCT01025180).
Other bias	Low risk	None was suspected.

Deliberato 2013

Methods	<p>Study design: parallel-group, open-label, randomized controlled trial</p> <p>Setting: ICU of a tertiary care, private hospital in São Paulo, Brazil. This open-model ICU is a 38-bed medical-surgical unit where approximately 2200 patients are admitted each year.</p>
Participants	<p>Inclusion criteria: patient with microbiologically confirmed infection (blood, urine, tracheal aspirate or bronchoalveolar lavage fluid cultures) with sepsis, severe sepsis and septic shock (ACCP/SCCM Consensus Conference Committee 1992 criteria). More than 50% of patients had bloodstream infection.</p> <p>Exclusion criteria: (1) start of antibiotic therapy more than 48 hours before the date when cultures were performed; (2) participants younger than 18 years of age; (3) known pregnancy; (4) infection requiring prolonged antibiotic therapy, such as bacterial endocarditis, hepatic or brain abscess, deep abscess, mediastinitis and osteomyelitis; (5) severe infection caused by viruses, parasites, fungi or mycobacteria; (6) chronic localized infection, such as chronic osteomyelitis or chronic prostatitis; (7) patients without indication for ICU admission, as determined by the attending physician; and (8) negative cultures (blood, urine, tracheal aspirate or bronchoalveolar lavage fluid) in participants with suspected sepsis, severe sepsis or septic shock</p>
Interventions	<p>Group 1 (N = 42): PCT group had PCT and CRP levels measured at day 0 (bacteraemia), 5 or 7 (if positive blood culture), and then every 48 hours until hospital discharge or death or until antibiotics were stopped. A predefined PCT protocol was used together with the clinical outcome to guide the physician's decision to discontinue antibiotics. The PCT protocol encouraged the physician to discontinue the antibiotics when (1) PCT dropped more than 90% from peak level or (2) an absolute value < 0.5 ng/mL was reached. Investigators did not interfere with the duration of prescribed antibiotic therapy.</p>

Deliberato 2013 (Continued)

Group 2 (N = 39): standard care in which all participants received antibiotic therapy based on the possible source of infection and the local susceptibility profile, as prescribed by the attending physician. By our local hospital policy, participants in the ICU cannot receive antibiotic therapy for longer than 14 days unless they have been specified as needing a prolonged duration of antibiotic therapy as the standard of care. Investigators did not interfere with the duration of prescribed antibiotic therapy.

Outcomes	<ol style="list-style-type: none"> 1. Duration of antibiotic therapy 2. In-hospital mortality 3. ICU mortality 4. ICU length of stay (days) 5. Recurrence of the initial infection 6. CRP levels 7. Costs: by using total costs of the antibiotic treatment used in both groups plus the cost of PCT used in the PCT group divided by the number of participants in each group (per protocol analysis)
Conflicts of interest and/or funding	None was detected.
Notes	<p>Sample size: Study authors estimated that inclusion of 29 participants in each study group would yield 90% power to detect a 40% reduction in exposure to the antibiotic, with a 2-tailed test of significance set at 0.05.</p> <p>PCT measures: automated test - VIDAS®BRAHMS PCT from bioMérieux (Rhône, France)</p> <p>Questions to study authors</p> <p>How do you define intention-to-treat analysis (ITT)?</p> <p>How do you define per-protocol analysis?</p> <p>Data showed 2 (4.8%) and 4 (10.3%) in-hospital mortalities by ITT analysis, respectively, in PCT and non-PCT groups. How did you find these numbers? Did you receive information from excluded participants?</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Folders were randomly and blindly assigned as "PCT group" or "standard group".
Allocation concealment (selection bias)	High risk	2 study authors randomly drew 1 folder from a black box containing 100 folders (50 "PCT group" and 50 "control group").
Blinding of participants and personnel (performance bias) All outcomes	High risk	investigators were aware of assignments.
Blinding of outcome assessment (detection bias) All outcomes	High risk	investigators were aware of assignments.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcomes were previously planned in the trial registered as NCT01494675. Study authors made available a clear flow of participants within the study. Additionally, they offered both intention-to-treat and available case analyses.
Selective reporting (reporting bias)	Low risk	Relevant outcomes were evaluated.

Deliberato 2013 (Continued)

Other bias	Low risk	None was suspected.
------------	----------	---------------------

Dharaniyadewi 2013

Methods	<p>Study design: parallel-group, randomized controlled trial</p> <p>Setting: emergency department in internal medicine (Cipto Mangunkusomo Hospital, Indonesia)</p>
Participants	<p>Inclusion criteria: septic participants (with at least 2 concomitant systemic inflammatory response syndrome criteria) older than 18 years with and without signs of organ hypoperfusion or dysfunction</p> <p>Exclusion criteria: not informed by study authors</p>
Interventions	<p>Group 1 (N = 100): semiquantitative PCT-examined patients</p> <p>Group 2 (N = 105): standard care: Semi-quantitative PCT test results will be informed to physicians taking care of participants</p>
Outcomes	<ol style="list-style-type: none"> 1. 14-Day mortality 2. Empirical antibiotic initiation ≤ 6 hours 3. Empirical antibiotic initiation > 6 hours 4. Appropriateness of empirical antibiotics 5. 14-Day mortality
Conflicts of interest and/or funding	None was detected.
Notes	<p>Sample size: not informed</p> <p>PCT measures: not informed</p> <p>A tropical infection consultant assessed the appropriateness of empirical antibiotics on the basis of Pedoman Umum Penggunaan Antibiotik Departemen Kesehatan Republik Indonesia.</p> <p>We had no success in contacting study authors.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information was provided by study authors.
Allocation concealment (selection bias)	Unclear risk	No information was provided by study authors.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information was provided by study authors.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information was provided by study authors.

Dharaniyadewi 2013 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Study authors made clear the flow diagram of participants within the study (per-protocol analysis). Outcomes were previously planned in the trial registered as NCT01862185.
Selective reporting (reporting bias)	High risk	Relevant outcomes were evaluated.
Other bias	High risk	Study authors did not provide detailed PCT algorithm for dealing with antimicrobial therapies.

Hochreiter 2009

Methods	<p>Study design: parallel-group, randomized controlled trial</p> <p>Setting: surgical intensive care ward at the West Coast Hospital Heide (Germany)</p>
Participants	<p>Inclusion criteria: participants requiring antibiotic therapy on the basis of confirmed or highly suspected bacterial infection and at least 2 concomitant SIRS criteria</p> <p>Exclusion criteria: not informed by study authors</p>
Interventions	<p>Group 1 (N = 57): PCT-guided antibiotic regimen based on confirmed or highly suspected bacterial infection. Antibiotic therapy was discontinued if clinical signs and symptoms of infection improved and PCT decreased to less than 1 ng/mL, or if the PCT value was greater than 1 ng/m: but had dropped to 25% to 35% of the initial value over 3 days. The physician in charge had the option to proceed with or adjust the antibiotic treatment if he or she had clinical reasons to do so, at any time point.</p> <p>Group 2 (N = 53): standard antibiotic regimen also based on confirmed or highly suspected bacterial infection. Antibiotic treatment was applied as standard regimen over 8 days. Also, the physician in charge had the option to proceed with or adjust the antibiotic treatment if he or she had clinical reasons to do so, at any time point.</p>
Outcomes	<ol style="list-style-type: none">1. Distribution of antibiotic classes2. Duration of antibiotic treatment (days)3. ICU length of stay (days)4. SOFA score5. Leucocyte count6. IL-6 concentrations7. CRP concentrations8. PCT concentrations9. Mortality (until hospital discharge)
Conflicts of interest and/or funding	SS has served as consultant and has received payments from BRAHMS AG for speaking engagements.
Notes	<p>Sample size: not informed</p> <p>PCT measures: by BRAHMS PCT LIA® (BRAHMS Aktiengesellschaft, Hennigsdorf, Germany)</p> <p>We had no success in contacting study authors.</p>
Risk of bias	
Bias	Authors' judgement Support for judgement

Hochreiter 2009 (Continued)

Random sequence generation (selection bias)	Unclear risk	Not informed
Allocation concealment (selection bias)	High risk	An open-label study as reported by study authors
Blinding of participants and personnel (performance bias) All outcomes	High risk	An open-label study as reported by study authors
Blinding of outcome assessment (detection bias) All outcomes	High risk	An open-label study as reported by study authors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Study authors made available a clear flow of participants within the study (all participants were analysed).
Selective reporting (reporting bias)	Low risk	Relevant outcomes were evaluated.
Other bias	Low risk	None was suspected.

Liu 2013

Methods	Study design: parallel-group, randomized controlled trial Setting: 1 University ICU (First Hospital of Jilin University, China)	
Participants	Inclusion criteria: participants aged ≥ 18 years with suspected bacterial sepsis, severe sepsis and septic shock, according to ACCP/SCCM Consensus Conference Committee 1992 criteria Exclusion criteria: bacterial culture results for <i>Pseudomonas aeruginosa</i> , <i>Aeromonas</i> , <i>Acinetobacter baumannii</i> , <i>Mycobacterium tuberculosis</i> or fungal infection; suspected virus or parasite infection; chronic localized infection; more than 48-hour antimicrobial drug treatment; immunodeficiency (HIV, white blood disease); patients with cancer	
Interventions	Group 1 (N = 42): Antibiotic therapy was guided by PCT results on a daily basis. When no active symptoms of infection were shown; acute physiology and APACHE II scores declined; and PCT values decreased by more than 90% or PCT value was lower than 0.25 µg/L - selected as drug withdrawal Group 2 (N = 40): regular antimicrobial therapy	
Outcomes	1. Time of antimicrobial drug (days) 2. Length of hospital stay (days) 3. ICU stay time (days) 4. Death in 28 days 5. Relapse in 28 days (not defined by study authors) 6. Clinical cure (not defined by study authors) 7. APACHE score	
Conflicts of interest and/or funding	None was detected.	
Notes	Sample size: No information was provided.	

Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock (Review)

Liu 2013 (Continued)

PCT measures:

Study authors followed-up discharged participants by telephone.

We had no success in contacting study authors.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not informed
Allocation concealment (selection bias)	Unclear risk	Not informed
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not informed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not informed
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No clear information was available about the flow of participants (all participants informed in the study were analysed).
Selective reporting (reporting bias)	Low risk	Relevant outcomes were evaluated.
Other bias	Low risk	None was suspected.

Nobre 2008

Methods	<p>Study design: parallel-group, open-label, randomized controlled trial</p> <p>Setting: tertiary care, University Hospitals of Geneva (Switzerland)</p>
Participants	<p>Inclusion criteria: all patients with suspected severe sepsis or septic shock admitted to the ICU (32-bed, mixed medical and surgical adult patients, with 3200 admissions per year). Patients developing severe sepsis or septic shock during their ICU stay were also considered for enrolment. Study authors used Bone 1992 criteria</p> <p>and reported 42% severe sepsis and 43% septic shock.</p> <p>Exclusion criteria: (1) microbiologically documented infection caused by <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i>, <i>Listeria</i> spp., <i>Legionella pneumophila</i>, <i>Pneumocystis jiroveci</i> or <i>Mycobacterium tuberculosis</i>, for which a prolonged duration of antibiotic therapy is standard of care (17); (2) severe infection due to viruses or parasites (e.g. haemorrhagic fever, malaria); (3) infectious condition requiring prolonged antibiotic therapy (e.g. bacterial endocarditis, brain abscess, deep abscesses); (4) antibiotic therapy started 48 hours or longer before enrolment; (5) chronic localized infection (e.g. chronic osteomyelitis); (6) severely immunocompromised patients, such as those infected with human immunodeficiency virus and with a CD4 count less than 200 cells/mm³, neutropenic patients (500 neutrophils/mm³) or patients receiving immunosuppressive therapy after solid organ transplantation; (7) withholding of life support; (8) absence of antimicrobial treatment despite clinical suspicion of sepsis</p>

Nobre 2008 (Continued)

Interventions	<p>Group 1 (N = 39): For participants with a favourable clinical course, investigators used predefined “stopping rules” based on circulating PCT levels to encourage caregivers to discontinue antibiotics. Participants with baseline PCT level greater than or equal to 1 mg/L were reevaluated at day 5. Investigators encouraged treating physicians to discontinue antibiotics when (1) PCT dropped by more than 90% from the baseline peak level, or (2) an absolute value below 0.25 mg/L was reached. Participants with PCT levels below 1 mg/L at baseline were reevaluated at day 3; treating physicians were encouraged to discontinue antibiotics when the PCT level was below 0.1 mg/L and careful clinical evaluation ruled out severe infection. However, the final decision concerning antibiotic therapy duration was always left to the discretion of the physician in charge.</p> <p>Group 2 (N = 40): standard practice, whereby participants received initial antibiotic therapy based on local guidelines and susceptibility patterns, according to the decision of the treating physician, who was unaware of the participant’s initial PCT levels; the final decision concerning antibiotic therapy duration was always left to the discretion of the physician in charge.</p>
Outcomes	<ol style="list-style-type: none"> 1. Duration of antibiotic treatment (days), defined as antibiotic therapy given for the first episode of infection for which the participant was included in the study 2. Incidence density of antibiotic exposure days, defined as a period of continuous administration of a single antibiotic agent with no interruption for longer than 24 hours per 1000 inpatient days. This variable included all antibiotics administered for longer than 24 hours during the study’s follow-up period (28 days). 3. Incidence rate ratio (IRR) of antibiotic exposure, calculated by the ratio of total antibiotic exposure days between control group and PCT group participants . 4. Days alive without antibiotics, defined as a period of at least 24 hours without antibiotic administration for a given participant, and comprising the entire follow-up period (28 days, unless death or discharge occurred earlier) 5. 28-Day mortality in-hospital 6. Length of stay in the ICU 7. Length of stay in the hospital 8. Clinical cure, defined as "clinical signs and symptoms present at baseline that had resolved by the final clinical assessment" 9. Recurrence of the initial infection 10. Recurrence of the nosocomial superinfection (a frequent complication of drug therapy for nosocomial infection, defined as if it became clinically apparent 48 hours after admission and was not incubating at admission, and within 48 hours after ICU discharge) 11. Sepsis-related mortality 12. Sepsis-unrelated mortality
Conflicts of interest and/or funding	SH and JP received speaker honoraria from BRAHMS AG.
Notes	<p>Sample size: The trial was designed to enrol at least 66 participants, to obtain power of 90% to detect a 33% (4 day) difference in duration of antibiotic therapy for the initial infection between the 2 groups based on an estimated baseline duration of 12 days. We assumed a standard deviation (SD) of 5 days in both groups and an error of 0.05.</p> <p>PCT measures: Kryptor-PCT (Brahms Diagnostica, Hennigsdorf, Germany)</p> <p>Other notes:</p> <ul style="list-style-type: none"> • All participants included in the study had circulating PCT levels measured at baseline and daily until the seventh day of follow-up (unless death or discharge occurred earlier), or until antibiotics were stopped in participants randomized to the PCT group. Thereafter, PCT was measured at 5-day intervals, even in those patients transferred to the ward. • Cases in which antibiotic treatment was continued despite the encouragement of investigators to stop it were classified as “algorithm overruling.” Finally, participants with positive blood cultures were ensured to receive at least 5 full days of parenteral antibiotic therapy.

Nobre 2008 (Continued)

- Broad-spectrum parenteral antibiotics were prescribed for participants with suspected severe sepsis or septic shock, depending on the suspected source of infection and microbiological cultures, when available.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-based random number generation
Allocation concealment (selection bias)	Low risk	Allocation was issued by using opaque, sealed, numbered envelopes.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label RCT
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open-label RCT
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary endpoints were first analysed on the basis of an intention-to-treat analysis, including all randomized participants. Additionally, study authors made available a clear flow of participants within the study.
Selective reporting (reporting bias)	Low risk	Outcomes were previously planned in clinicaltrials.gov NCT 00250666. Relevant outcomes were evaluated.
Other bias	Low risk	None was suspected.

Oliveira 2013

Methods	<p>Study design: parallel-group, open-label, randomized controlled trial</p> <p>Setting: 2 teaching ICUs (Brazil)</p>
Participants	<p>Inclusion criteria: all adult patients 18 years of age or older with suspected severe sepsis or septic shock (according to Bone 1992; Levy 2003 criteria).</p> <p>Study authors reported 63% severe sepsis and 55.6% septic shock.</p> <p>Exclusion criteria: (1) confirmed microbiological infection by <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i>, <i>Listeria</i> species, <i>Mycobacterium tuberculosis</i> or fungi; (2) <i>Staphylococcus aureus</i> bacteraemia; (3) suspected or confirmed severe infection caused by virus or parasite; (4) infection that required long-term treatment, regardless of the etiologic agent (e.g. bacterial endocarditis); (5) localized chronic infection (e.g. chronic osteomyelitis); (6) more than 48 hours of antibiotic treatment; (7) immunosuppressed patients (such as those diagnosed with HIV), patients with neutropenia (less than 500 neutrophils/mm³), patients post solid organ transplant, patients receiving immunosuppressive therapy and patients who received more than 1 mg/kg of prednisone or equivalent; (8) patients under palliative care; (9) patients who suffered multiple trauma, burns or major surgery in the previous 5 days; (10) patients given a diagnosis of pulmonary neoplasia, carcinoid tumour or medullary tumour of the thyroid; and (11) patients who remained in the ICU for no longer than 24 hours</p>
Interventions	<p>Group 1 (N = 50): protocol based on serum PCT levels. Daily measurements, every 48 hours for 2 measurements in participants remaining in the ICU, then every 5 days. The duration of antibiotic therapy</p>

Oliveira 2013 (Continued)

was based on circulating PCT levels. Investigators proposed interruption of antibiotics if a relative reduction of 90% in baseline PCT levels, or if an absolute value lower than 0.1 ng/mL, was reached.

Group 2 (N = 47): protocol based on serum CRP levels. Daily measurements, every 48 hours for 2 measurements in participants remaining in the ICU, then every 5 days. The duration of antibiotic therapy was based on circulating CRP levels. Investigators proposed interruption of antibiotics if a relative reduction of 50% in baseline CRP levels, or if a value lower than 25 mg/dL, was reached.

Outcomes	<ol style="list-style-type: none"> 1. Duration of antibiotic therapy for the first episode of infection, defined as the period of antibiotic use for at least 24 hours during the 28 days of follow-up 2. Total number of days receiving antibiotic therapy 3. Days off antibiotic therapy, defined as a period of at least 24 hours without the use of any antibiotics during 1000 live days of hospitalization 4. Death from any cause during the 28 days of follow-up in the hospital 5. Length of stay in the ICU 6. Length of stay in the hospital 7. Clinical cure, defined as the disappearance of signs and symptoms of infection observed at inclusion in the study 8. Recurrent infection, defined as persistence of the pathogen originally causing the infection 9. Nosocomial infection (courses of antimicrobial therapy administered at an interval longer than 48 hours were considered directed to distinct infection episodes) 10. Protocol overruling <p>Participants were followed up for 28 days, or until death or hospital transference, whichever came first.</p>
----------	---

Conflicts of interest and/or funding	Dr Nobre was paid for lectures by bioMérieux.
--------------------------------------	---

Notes	<p>Sample size: based on duration of antibiotic therapy in participants treated with a PCT-guided protocol; would be at least 25% shorter than the duration observed in participants treated according to a protocol based on serum CRP levels, resulting in 58 participants per group - totalling 116 individuals (power of 80% and alpha error of 5%)</p> <p>PCT measures: Vidas BRAHMS PCT (bioMérieux, Lyon, France)</p> <p>CRP measures: Reactive test VITROS (Johnson & Johnson Clinical Diagnostics, Inc., Rochester, NY) was used to quantitatively measure the concentration of serum or plasma CRP.</p>
-------	--

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random computer-generated numbers. Sealed opaque envelopes were used for randomization.
Allocation concealment (selection bias)	Low risk	Sealed opaque envelopes were used for randomization.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open-label RCT
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open-label RCT
Incomplete outcome data (attrition bias)	Low risk	Study authors made available a clear flow of participants within the study (per-protocol analysis).

Oliveira 2013 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	Relevant outcomes were evaluated. Protocol was registered at ClinicalTrials.org (NCT00934011).
Other bias	Low risk	None was suspected.

Schroeder 2009

Methods	<p>Study design: parallel-group, open-label, randomized controlled trial</p> <p>Setting: ICU of the Department of Anesthesiology and Intensive Care Medicine at Westküstenklinikum Heide (Germany)</p>	
Participants	<p>Inclusion criteria: patients after abdominal surgery and after the start of antibiotic treatment with the diagnosis of severe sepsis (according to ACCP/SCCM Consensus Conference Committee 1992 criteria)</p> <p>Exclusion criteria: patients who did not meet the inclusion criteria, who refused informed consent or who already had received antibiotic treatment before admission to the ICU</p>	
Interventions	<p>Group 1 (n = 14): Antibiotic therapy was discontinued if clinical signs and symptoms of sepsis improved and PCT values decreased to 1 ng/mL or less or dropped to 25% to 35% of the initial PCT concentration over 3 consecutive days, but the physician in charge was always free to decide whether to continue or change the antibiotic regimen upon clinical judgement. Daily standard routine laboratory analysis including C-reactive protein (CRP) was performed. Participants were also subjected to daily standard routine laboratory analysis, including CRP.</p> <p>Group 2 (n = 13): Antibiotic treatment was discontinued according to clinical signs and empirical rules, but the physician in charge was always free to decide whether to continue or change the antibiotic regimen upon clinical judgement. Participants were also subjected to daily standard routine laboratory analysis, including CRP, in the same way as those in the PCT group.</p>	
Outcomes	<ol style="list-style-type: none"> 1. Length of hospital stay 2. Length of intensive care unit (ICU) stay (days) 3. Duration of antibiotic treatment (days) 4. PCT concentration 5. C-reactive protein (CRP) levels 6. Participants receiving the following antibiotic substances: acylaminopenicillin + beta lactamase inhibitor; acylaminopenicillin + nitroimidazole and carbapenem 7. SOFamax, defined as the "highest Sequential Organ Failure Assessment Score during the study period" 8. Mortality until hospital discharge 	
Conflicts of interest and/or funding	The corresponding author declared speaking engagements for BRAHMS AG.	
Notes	<p>Sample size: Duration of antibiotic therapy for participants treated with a PCT-guided protocol would be at least 25% shorter than the duration observed in participants treated according to a protocol based on serum CRP levels, resulting in 58 participants per group - totalling 116 individuals (power of 80% and alpha error of 5%).</p> <p>PCT measures: BRAHMS PCT LIA® - B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf (Germany)</p> <p>We had no success in contacting study authors.</p>	

Risk of bias

Schroeder 2009 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not informed
Allocation concealment (selection bias)	Unclear risk	Not informed
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not informed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not informed
Incomplete outcome data (attrition bias) All outcomes	Low risk	Study authors made available a clear flow of participants within the study (all participants were analysed).
Selective reporting (reporting bias)	Low risk	Relevant outcomes were evaluated.
Other bias	Low risk	None was suspected.

Shehabi 2014

Methods	<p>Study design: parallel-group, randomized controlled trial</p> <p>Setting: 11 general academic and non-academic ICUs (Australia)</p>
Participants	<p>Inclusion criteria: patients >18 years of age, admitted to ICU within previous 72 hours, receiving parenteral and/or enteral antibiotics for a suspected bacterial infection (2) (with 2 or more systemic inflammatory response syndrome criteria) and expected to remain in the ICU for longer than 24 hours</p> <p>Exclusion criteria: patients receiving antibiotics for surgical prophylaxis or with proven bacterial infection requiring more than 3 weeks of antibiotic therapy, with isolated systemic fungal or systemic viral infection in the absence of bacterial infection, with neutropenia with a neutrophil count less than 1000 cells/mm³, receiving immunosuppressive agents, undergoing cardiac surgery or trauma or heat stroke within 48 hours, with medullary thyroid or small cell lung cancer, not expected to survive to hospital discharge or with known pregnancy</p>
Interventions	<p>Group 1 (N = 200): Clinicians could order additional PCT levels after day 7 at their discretion. Daily PCT results were made available to the treating clinician. Antibiotics were prescribed according to Australian Antibiotics Therapeutic Guidelines (24) and antimicrobial stewardship (implemented by infectious diseases twice-weekly rounds and on the basis of need consultations). Physicians were recommended to cease antibiotics if initial or any subsequent PCT was negative at level < 0.10 ng/mL; if initial or any subsequent PCT was borderline - level 0.10 to 0.25 ng/mL - and infection was highly unlikely; or if subsequent PCT level declined by more than 90% from baseline. Investigators sought to assess antibiotic appropriateness and/or adequacy of source control if PCT level at 48 hours was greater than 70% of baseline value.</p> <p>Group 2 (N = 200): standard care, with clinicians blinded to PCT levels; results were faxed directly to the Clinical Informatics and Data Management Unit, Department of Epidemiology and Preventive Medicine. Antibiotics were prescribed according to the Australian Antibiotics Therapeutic Guidelines and an-</p>

Shehabi 2014 (Continued)

timicrobial stewardship (implemented by infectious diseases twice-weekly rounds and on the basis of need consultations).

Outcomes	<ol style="list-style-type: none"> 1. Antibiotic cessation at 28 days 2. Hospital discharge 3. Hospital mortality 4. Antibiotic-free days at day 28 5. Number of antibiotics daily defined doses (DDD) at day 28 6. ICU length of stay 7. Hospital length of stay 8. 90-Day all-cause mortality 9. Emergence of resistant micro-organisms 10. Number of algorithm violations 11. Readmission ICU reinfection 12. Isolates with multi-resistant organisms defined according to microbiological sensitivity and minimum inhibitory concentration (MIC) to standard antibiotics 13. Therapy withdrawn in hospital
Conflicts of interest and/or funding	Material support was provided by Roche Diagnostics, Thermo Fisher Scientific and BioMérieux. Roche Diagnostics and Thermo Fisher Scientific provided additional unrestricted grant funding.
Notes	Sample size: Study authors assumed a 25% (2.3 days) reduction in antibiotic treatment from baseline of 9 days. To further account for potential dropout or loss to follow-up (anticipated to be < 5%), a total of 400 participants were recruited (sample power of 90%).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomization (via a secured central study website) by block (1:1 ratio) and stratified according to the presence of septic shock (defined by receipt of inotrope and/or any vasopressors within the previous 24 hours)
Allocation concealment (selection bias)	Low risk	Randomization via a secured central study website
Blinding of participants and personnel (performance bias) All outcomes	High risk	Physicians who treated participants were aware of the assignments.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Although data management was conducted by a central body with a blinded statistician, physicians who collected data were aware of the assignments.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Study authors made available a clear flow of participants within the study (per-protocol analysis).
Selective reporting (reporting bias)	Low risk	Relevant outcomes were evaluated. Protocol was registered in the ANZRC 01111-1117-1760 (ACTRN12610000809033).
Other bias	Low risk	None was suspected.

Svoboda 2007

Methods	<p>Study design: parallel-group, randomized controlled trial</p> <p>Setting: 04 traumatological ICUs (Czech)</p>
Participants	<p>Inclusion criteria: multiple trauma participants aged ≥ 18 years who developed sepsis (according to Bone 1992 criteria).</p> <p>Study authors reported septic shock in 71% and 68% in PCT vs non-PCT comparison groups, respectively.</p> <p>Exclusion criteria: patients with chemical or burn trauma; with death perceived to be imminent; or who had been designated as "not full support" or "do not resuscitate"</p>
Interventions	<p>Group 1 (N = 38): treatment decision according to PCT level. For severe sepsis with PCT > 2 ng/mL and signalized bacteraemia, clinicians were motivated to change antibiotics and catheters; participants with PCT ≤ 2 ng/mL and confirmed localized infection were subjected to ultrasonography and/or CT, followed by repeated surgical treatment (drainage, reoperation).</p> <p>Group 2 (N = 34): standard evaluation of all parameters by consultant surgeon according to treatment protocol of the health service. Standard supportive care, broad-spectrum antibiotics and change of intravascular catheters were provided to all septic patients according to evidence-base guidelines.</p>
Outcomes	<ol style="list-style-type: none"> 1. Length of ICU stay 2. Days on mechanical ventilation 3. SOFA score until day 28 4. 28-Day mortality 5. PCT > 2 ng/mL, 5 days after randomization 6. Repeated surgery, 5 days after randomization 7. Time to resurgery, 5 days after randomization 8. CRP, 5 days after randomization 9. IL-6 (pg/mL), 5 days after randomization 10. TNF (pg/mL), 5 days after randomization 11. Antithrombin III, 5 days after randomization
Conflicts of interest and/or funding	None was suspected.
Notes	<p>Sample size: not informed</p> <p>PCT measures: PCT-Q, B.R.A.H.M.S., Hennigsdorf (Germany)</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random number table
Allocation concealment (selection bias)	Low risk	Study authors used opaque sealed numbered envelopes.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not informed

Svoboda 2007 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not informed
Incomplete outcome data (attrition bias) All outcomes	Low risk	Study authors made available a clear flow of participants within the study (all participants were analysed).
Selective reporting (reporting bias)	Low risk	Relevant outcomes were evaluated.
Other bias	Low risk	None was suspected.

ACCP: American College of Chest Physicians.

APACHE: Acute Physiology and Chronic Health Evaluation.

CD4: cluster of differentiation 4.

CRP: C-reactive protein.

DDD: daily defined doses.

HIV: human immunodeficiency virus.

ICU: intensive care unit.

IL: interleukin.

IRR: incidence rate ratio.

ITT: intention-to-treat analysis.

mg/dL: milligrams per decilitre.

MIC: minimum inhibitory concentration.

mL: millilitre.

N: total number of participants.

ng/mL: nanogram per millilitre.

PCT: procalcitonin.

pg/mL: picogram/ millilitre.

PO₂: partial pressure of oxygen.

RCT: randomized controlled trial.

SCCM: Society of Critical Care Medicine.

SD: standard deviation.

SIRS: systemic inflammatory response syndrome.

SOFA: sequential organ failure assessment.

TNF: tumour necrosis factor.

µg/L: microgram per litre.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Bodmann 2016	Retrospective study design
Bouadma 2010	RCT. Inclusion criteria not specific for sepsis, severe sepsis and/or septic shock (participants with suspected bacterial infection, with no clear definition for diagnosis of sepsis)
Bréchet 2015	Economic analysis
Harrison 2015	Economic analysis
Jensen 2011	RCT with critically ill participants. Inclusion criteria not specific for sepsis, severe sepsis and/or septic shock
Kiehntopf 2011	Retrospective study design

Study	Reason for exclusion
Kip 2015	Economic evaluation
Kolici 2013	RCT in neonates
Kopterides 2010	Systematic review
Layios 2012	RCT. Inclusion criteria not specific for sepsis, severe sepsis and/or septic shock
Lima 2016	RCT. Inclusion criteria strict for febrile neutropenia
Mann 2011	Systematic review
Pantelidou 2015	Narrative review
Prkno 2013	Systematic review
Sandifer 2012	Systematic review
Schuetz 2011	Systematic review
Schuetz 2013	Narrative review
Soni 2013	Systematic review
Stocker 2010a	RCT in neonates
Stocker 2010b	RCT in neonates
Ternhag 2010	Narrative review for chronic obstructive pulmonary disease
Westwood 2015	Economic evaluation

RCT: randomized controlled trial.

Characteristics of studies awaiting assessment *[ordered by study ID]*

[Bloos 2016](#)

Methods	<p>Study design: multi-centre, randomized, placebo-controlled trial</p> <p>Setting: ICUs from 35 hospitals in Germany</p>
Participants	<p>Inclusion criteria: severe sepsis/septic shock (ACCP/SCCM criteria), onset < 24 hours), ≥ 18 years of age</p> <p>Exclusion criteria: pregnancy or breast-feeding, fertile female women not using contraceptive treatment, concomitant participation in any study (last 30 days), previous participation in this trial, selenium intoxication, no compliance with instructions of the study, imminent possibility of death due to coexisting disease(s), relationship of the participant to one or more members of the study team, long-lasting duration of antimicrobial therapy due to infectious diseases (i.e. endocarditis, tuberculosis, malaria, etc), immunocompromised participants</p>
Interventions	<p>Group 1 (N = 552): PCT-based algorithm, both with and without sodium-selenite</p> <p>Group 2 (N = 537): no PCT-based algorithm (antimicrobial therapy according to the discretion of the treating physician), both with and without sodium-selenite</p>

Bloos 2016 (Continued)

Sodium-selenite 1000 µg/d until the end of ICU treatment or for ≤ 21 days

PCT was measured at randomization and at days 4, 7, 10 and 14.

Outcomes	<ol style="list-style-type: none"> 1. All-cause mortality (28 days) 2. All-cause mortality (90 days) 3. Mean total SOFA and SOFA subscores 4. Frequency and duration of mechanical ventilation (90 days) 5. Frequency and duration of vasopressor support 6. Frequency of adverse events and severe adverse events 7. Clinical cure and microbiological cure (days 4, 7, 10, 14) 8. Duration of antimicrobial therapy 9. Costs of antimicrobial therapy 10. Time to change of antibiotic therapy 11. Days alive without antimicrobial therapy 12. Frequency of resistances against antibiotics 13. ICU length of stay (90 days) 14. Hospital length of stay (90 days) 15. Rate of surgical procedures for focus control 16. Rate of procedures performed to diagnose infection 17. Frequency of new infections
Notes	<p>Sample size: not available</p> <p>PCT measures: (BRAHMS, Germany; PCT-sensitive KRYPTOR Compact)</p> <p>Financial support/funding: Kompetenznetz Sepsis, Biosyn, Brahms AG</p>

de Jong 2016

Methods	<p>Study design: multi-centre, randomized, open-label, controlled trial</p> <p>Setting: ICUs from 15 hospitals in the Netherlands.</p>
Participants	<p>Inclusion criteria: > 18 years, antibiotics initiated for suspected or proven infection on admission or during ICU admission</p> <p>Exclusion criteria: > 3 weeks of prolonged antibiotic therapy for infectious clinical conditions such as endocarditis and cerebral/hepatic abscess; severe infections due to viruses, parasites or tuberculosis; ICU admission for exclusive short-term postoperative follow-up; anticipated length of stay < 24 hours; cystic fibrosis; severely immunocompromised (e.g. HIV and CD4 count < 200 cells/mm, neutropenic patients (< 500 neutrophils/mL)); solid organ transplantation; moribund participants</p>
Interventions	<p>Group 1 (N = 761): to discontinue antibiotics when procalcitonin concentration had decreased by at least 80% or was ≤ 0.5 µg/L</p> <p>Group 1 (N = 785): local antibiotic protocols</p>
Outcomes	<ol style="list-style-type: none"> 1. Mortality (28 days) 2. Mortality (1 year) 3. Consumption of antibiotics (defined daily dosage) 4. Time of antibiotic therapy (days) 5. Length of ICU stay 6. Costs of antibiotics (until 28 days in euros)

de Jong 2016 (Continued)

7. Costs of procalcitonin (until 28 days in euros)

Notes	<p>Sample size: Study authors estimated 1816 participants, based on a mean baseline antibiotic duration of 8 days, type I error = 5%; type II error = 90% and drop-out rate of 20%.</p> <p>PCT measures: automated Kryptor platform (Thermo Fisher Scientific, Hennigsdorf, Germany), Roche Elecsys Thermo Fisher Scientific PCT assay, Siemens Centaur Thermo Fisher Scientific PCT assay or BioMerieux Vidas Thermo Fisher Scientific PCT assay</p> <p>Financial support/funding: Thermo Fisher Scientific</p>
-------	---

Najafi 2015

Methods	<p>Study design: single-centre, randomized, single-blind, controlled trial</p> <p>Setting: 1 ICU, Tehran</p>
Participants	<p>Inclusion criteria: Patients with SIRS, according to at least 2 of the following criteria: body temperature $> 38^{\circ}\text{C}$ or $< 36^{\circ}\text{C}$, tachycardia $> 90/\text{min}$, tachypnoea $> 20/\text{min}$ and leucocytosis $> 12 \times 10^9/\text{L}$ or a leftward shift with more than 10% band cells or leukopenia $< 4 \times 10^9/\text{L}$</p> <p>Exclusion criteria: documented infection, pus from wound or abscess, empyema, thrombophlebitis, infection due to virus or parasites, hypoxaemia ($\text{PO}_2 < 60 \text{ mmHg}$), oliguria (urine output $< 30 \text{ mL/h}$), Glasgow Coma Scale score of 3 without sedation, parenteral antibiotic usage (24 hours before admission to ICU), hospitalization (48 hours before enrolment), conditions requiring prolonged antibiotic therapy (e.g. endocarditis, chronic localized infection such as osteomyelitis), severely immunocompromised patients</p>
Interventions	<p>Group 1 (N = 30): antibiotic treatment based on serum level of PCT (measured during 4-6 hours). PCT $< 0.5 \text{ ng/mL}$ (no antimicrobial treatment, new measurement after 12 hours); PCT $0.5\text{-}2.0 \text{ ng/mL}$ (no antimicrobial treatment, new measurement after 8 hours); and PCT $\geq 2 \text{ ng/mL}$ (antimicrobial treatment recommended)</p> <p>Group 2 (N = 30): antibiotic empirical therapy</p>
Outcomes	<ol style="list-style-type: none"> 1. Total antibiotic exposure (days) 2. SOFA score on the first day 3. SOFA score on the second day 4. Clinical cure 5. In-hospital mortality 6. ICU stay 7. Hospital length of stay (days)
Notes	<p>Sample size: Study authors estimated 60 participants, based on 95% power to detect a 30% reduction in the use of antibacterial agents.</p> <p>PCT measures: PCT levels were measured with time-resolved amplified cryptate emission (TRACE) assay (BRAHMS, Germany; PCT-sensitive KRYPTOR Compact)</p> <p>Financial support/funding: not reported</p>

DATA AND ANALYSES

Comparison 1. PCT versus non-PCT (standard care or CRP: primary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at longest follow-up	10	1156	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.65, 1.01]
2 Mortality at 28 days	4	324	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.59, 1.28]
3 Mortality at ICU discharge	3	506	Risk Ratio (M-H, Random, 95% CI)	1.03 [0.50, 2.11]
4 Mortality at hospital discharge	7	805	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.75, 1.27]
5 Time receiving antimicrobial therapy (days) - mean (SD)	4	313	Mean Difference (IV, Random, 95% CI)	-1.28 [-1.95, -0.61]
6 Time receiving antimicrobial therapy (days) - median (IQR)			Other data	No numeric data

Analysis 1.1. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 1 Mortality at longest follow-up.

Analysis 1.2. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 2 Mortality at 28 days.

Analysis 1.3. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 3 Mortality at ICU discharge.

Analysis 1.4. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 4 Mortality at hospital discharge.

Study or subgroup	Procalcitonin n/N	Non-procalcitonin n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Test for overall effect: Z=0.19(P=0.85)					
Favours procalcitonin 0.001 0.1 1 10 1000 Favours non-procalcitonin					

Analysis 1.5. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 5 Time receiving antimicrobial therapy (days) - mean (SD).

Study or subgroup	Procalcitonin		non-procalcitonin		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
Hochreiter 2009	57	5.9 (1.7)	53	7.9 (0.5)		29.01%	-2[-2.46,-1.54]
Liu 2013	42	8.1 (0.3)	40	9.3 (0.3)		33.24%	-1.2[-1.33,-1.07]
Oliveira 2013	49	8.1 (3.7)	45	7.2 (3.5)		12.97%	0.9[-0.56,2.36]
Schroeder 2009	14	6.6 (1.1)	13	8.3 (0.7)		24.77%	-1.7[-2.39,-1.01]
Total ***	162		151			100%	-1.28[-1.95,-0.61]
Heterogeneity: Tau ² =0.35; Chi ² =20.72, df=3(P=0); I ² =85.52%							
Test for overall effect: Z=3.76(P=0)							
Favours procalcitonin -10 -5 0 5 10 Favours non-procalcitonin							

Analysis 1.6. Comparison 1 PCT versus non-PCT (standard care or CRP: primary outcomes), Outcome 6 Time receiving antimicrobial therapy (days) - median (IQR).

Study	Time receiving antimicrobial therapy (days) - median (IQR)			P-value	Favoured group
	Procalcitonin, median (range / interquartile range [IQR])	non-Procalcitonin, median (range / interquartile range [IQR])	Difference between medians		
Annane 2013	5 (IQR: 2-5)	5 (IQR: 3-5)	0 days	0.52	Procalcitonin
Deliberato 2013	9 (Range: 5-24)	13 (Range: 3-45)	4 days	0.008	Procalcitonin
Oliveira 2013	13 (IQR: 7-18)	8 (IQR: 6-18)	5 days	0.183	non-Procalcitonin

Comparison 2. PCT versus non-PCT (standard care or CRP: secondary outcomes)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Hospital length of stay (days) - median (IQR) or mean (SD)			Other data	No numeric data
2 ICU length of stay (days) - mean (SD)	4	291	Mean Difference (IV, Random, 95% CI)	-2.05 [-3.14, -0.97]
3 ICU length of stay (days) - median (IQR)			Other data	No numeric data
4 SOFA score during ICU stay			Other data	No numeric data
5 SOFA score at day 3			Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6 SOFA score at day 5			Other data	No numeric data
7 SOFA _{max} score			Other data	No numeric data
8 APACHE II score			Other data	No numeric data
9 Reinfection (primary infection relapse)	3	213	Risk Ratio (M-H, Random, 95% CI)	1.84 [0.43, 7.89]
10 Duration of mechanical ventilation (days)			Other data	No numeric data

Analysis 2.1. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 1 Hospital length of stay (days) - median (IQR) or mean (SD).

Study	Hospital length of stay (days) - median (IQR) or mean (SD)				P-value	Favoured group
	Procalcitonin median (Range / interquartile range IQR) or mean (SD)	non-Procalcitonin median (Range / interquartile range IQR) or mean (SD)	Mean difference	Difference between medians		
Annane 2013	27 (IQR: 9–49)	33.0 (IQR: 11–69)	not informed	6 days	0.22	procalcitonin
Deliberato 2013	10.5 (Range: 5–547)	14.0 (Range: 2–82)	not informed	3.5 days	0.34	procalcitonin
Liu 2013	27 (4.9 SD)	32 (5.4 SD)	5 days	not applied	<0.0001 (Z-test)	procalcitonin
Nobre 2008	14.0 (Range: 5–64)	21.0 (Range: 5–89)	not informed	7 days	0.16	procalcitonin
Oliveira 2013	36 (IQR: 20–59)	25 (IQR: 13–52)	not informed	11 days	0.175	non-procalcitonin
Shehabi 2014	15 (IQR: 9–29)	17 (IQR: 10–32)	not informed	2 days	0.19	procalcitonin

Analysis 2.2. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 2 ICU length of stay (days) - mean (SD).

Analysis 2.3. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 3 ICU length of stay (days) - median (IQR).

Study	Procalcitonin, median (range / interquartile range [IQR])	ICU length of stay (days) - median (IQR)		P-value	Favoured group
		non-Procalcitonin, median (range / interquartile range [IQR])	Difference between medians		
Annane 2013	22 (IQR: 8-42)	23 (IQR: 10-60)	1 day	0.58	Procalcitonin
Deliberato 2013	3.5 (Range: 1-57)	4 (Range: 1-28)	0.5 days	0.80	Procalcitonin
Nobre 2008	3 (Range: 1-18)	5 (Range: 1-30)	2 days	0.03	Procalcitonin
Oliveira 2013	14 (IQR: 9-24)	12 (IQR: 7-18)	2 days	0.164	non-Procalcitonin
Shehabi 2014	6 (IQR: 3-9.5)	6 (IQR: 4-10)	0 days	0.87	Procalcitonin

Analysis 2.4. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 4 SOFA score during ICU stay.

Study	Procalcitonin, Mean (SD) (N = 38)	SOFA score during ICU stay		P-value	Favoured group
		non-Procalcitonin, Mean (SD) (N = 34)	Mean difference (95% CI)		
Svoboda 2007	7.9 (2.8)	9.3 (3.3)	-1.40 [-2.82, 0.02]	0.05	Procalcitonin

Analysis 2.5. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 5 SOFA score at day 3.

Study	SOFA score at day 3		P-value
	Procalcitonin, median (interquartile range [IQR])	non-Procalcitonin, median (interquartile range [IQR])	
Annane 2013	8 (5-10)	8 (7-11)	0.85

Analysis 2.6. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 6 SOFA score at day 5.

Study	SOFA score at day 5		P-value
	Procalcitonin, median (interquartile range [IQR])	non-Procalcitonin, median (interquartile range [IQR])	
Annane 2013	8 (5-9)	8 (7-11)	0.61

Analysis 2.7. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 7 SOFA_{max} score.

Study	SOFA _{max} score		P-value	Favoured group
	Procalcitonin, Mean (95% CI) (N = 14)	non-Procalcitonin, Mean (95% CI) (N = 13)		
Schroeder 2009	7.3 (3.5)	8.4 (4.2)	-1.00 (-3.93, 1.93)	0.50

Analysis 2.8. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 8 APACHE II score.

Study	Procalcitonin, Mean (SD) (N = 42)	non-Procalcitonin, Mean (SD) (N = 40)	APACHE II score Mean difference (95% CI)	P-value	Favoured group
Liu 2013	5.7 (0.9)	6.2 (1.3)	0.50 (3.54, 4.54)	0.81	non-procalcitonin

Analysis 2.9. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 9 Reinfection (primary infection relapse).

Analysis 2.10. Comparison 2 PCT versus non-PCT (standard care or CRP: secondary outcomes), Outcome 10 Duration of mechanical ventilation (days).

Study	Procalcitonin, median (interquartile range [IQR]) or mean (SD)	non-Procalcitonin, median (interquartile range [IQR]) or mean (SD)	Duration of mechanical ventilation (days) Difference between medians or Difference between means (95% CI)	P-value	Favoured group
Annane 2013	11 (IQR: 5–25)	14 (IQR: 8–25)	3 days	0.56	procalcitonin
Shehabi 2014	4 (IQR: 2–9)	4 (IQR: 2–11)	0 days	0.99	procalcitonin
Svoboda 2007	10.3 (7.8 SD)	13.9 (9.4 SD)	3.6 days (0.42, 7.62)	0.08	procalcitonin

Comparison 3. PCT versus non-PCT - other outcomes of potential interest

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at 5 days			Other data	No numeric data
2 Mortality at 14 days			Other data	No numeric data
3 Mortality at 90 days			Other data	No numeric data
4 Sepsis-related death*	2	488	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.50, 1.59]
5 Septic shock-related death			Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6 Patients on antibiotics at day 5 (last information carried over for non-survivors)			Other data	No numeric data
7 Patients on antibiotics at day 5 (non-survivors considered as being treated with antibiotic)			Other data	No numeric data
8 Patients on antibiotics at day 1 (among survivors)			Other data	No numeric data
9 Patients on antibiotics at day 5 (survivors only)			Other data	No numeric data
10 Therapy withdrawn in hospital			Other data	No numeric data
11 Appropriate empirical antibiotics			Other data	No numeric data
12 Empirical antibiotic initiation ≤ 6 hours			Other data	No numeric data
13 Empirical antibiotic initiation > 6 hours			Other data	No numeric data
14 Infection at day 3			Other data	No numeric data
15 Infection at day 5			Other data	No numeric data
16 Infection at any time point after randomization			Other data	No numeric data
17 Nasal swabs positive for methicillin-resistant <i>Staphylococcus aureus</i>			Other data	No numeric data
18 Rectal swabs positive for extended-spectrum β -lactamase-resistant			Other data	No numeric data
19 Rectal swabs positive for <i>Enterobacter</i> , <i>Klebsiella</i>			Other data	No numeric data
20 Readmission due to secondary infection			Other data	No numeric data
21 Isolates with multi-resistant organisms			Other data	No numeric data
22 Nosocomial infection	2	162	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.77, 1.51]
23 Antibiotic therapy-free days (mean, SD) - PCT vs standard care			Other data	No numeric data
24 Antibiotic therapy-free days (median, IQR) - PCT vs standard care			Other data	No numeric data
25 Antibiotic therapy-free days - PCT vs CRP			Other data	No numeric data
26 Duration of first episode of antibiotic treatment (days)*			Other data	No numeric data
27 Days of antibiotic exposure per 1000 inpatient days			Other data	No numeric data

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
28 All antibiotics total daily defined dose Irrespective of the antimicrobial			Other data	No numeric data
29 Antibiotics "stopped earlier" (hazard ratio)			Other data	No numeric data
30 Antibiotics "stopped earlier" (hazard ratio) adjusted for disease severity			Other data	No numeric data
31 Time to antibiotic cessation at day 28			Other data	No numeric data
32 Duration of first episode of antibiotic treatment (days)			Other data	No numeric data
33 Antibiotic therapy-free days according to different subgroups			Other data	No numeric data
33.1 Suspected sepsis			Other data	No numeric data
33.2 Suspected septic shock			Other data	No numeric data
33.3 Confirmed positive culture			Other data	No numeric data
33.4 Negative culture			Other data	No numeric data
33.5 Positive blood culture			Other data	No numeric data
33.6 Positive pulmonary culture			Other data	No numeric data
34 World Health Organization daily defined dose per 100 occupied bed days			Other data	No numeric data
35 Antibiotics maintained for 7 days because of bacteraemia and/or a SOFA score above 10 at inclusion			Other data	No numeric data
36 Antibiotic therapy discontinuation in the first episode of infection*			Other data	No numeric data
37 Protocol overruling			Other data	No numeric data
38 Clinical cure*	3	244	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.90, 1.13]
39 Total costs with antibiotics per comparison group (USD)			Other data	No numeric data
40 Mean cost with antibiotics + PCT kit per participant (USD)			Other data	No numeric data
41 Cost reduction for antibiotic treatment			Other data	No numeric data

Analysis 3.1. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 1 Mortality at 5 days.

Study	Mortality at 5 days				P-value	Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)			
Anname 2013	3/31	3/31	1.00 (0.22, 4.58)	1.0		no group

Analysis 3.2. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 2 Mortality at 14 days.

Study	Mortality at 14 days				P-value	Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	RR (95% CI)			
Dharaniyadewi 2013	26/95	53/102	0.53 (0.36, 0.77)	0.00086		Procalcitonin

Analysis 3.3. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 3 Mortality at 90 days.

Study	Mortality at 90 days				P-value	Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	RR (95% CI)			
Shehabi 2014	36/196	31/198	1.14 (0.73, 1.77)	0.56		non-Procalcitonin

Analysis 3.4. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 4 Sepsis-related death*.

Analysis 3.5. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 5 Septic shock-related death.

Study	Septic shock-related death				P-value	Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)			
Shehabi 2014	14/196	16/198	0.88 (0.44, 1.76)	0.73		non-Procalcitonin

Analysis 3.6. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 6 Patients on antibiotics at day 5 (last information carried over for non-survivors).

Study	Patients on antibiotics at day 5 (last information carried over for non-survivors)				P-value	Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)			
Anname 2013	18/30	22/28	0.76 (0.54, 1.08)	0.13		Procalcitonin

Analysis 3.7. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 7 Patients on antibiotics at day 5 (non-survivors considered as being treated with antibiotic).

Study	Patients on antibiotics at day 5 (non-survivors considered as being treated with antibiotic)				Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)	P-value	
Annane 2013	21/30	23/28	0.85 (0.64, 1.14)	0.28	Procalcitonin

Analysis 3.8. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 8 Patients on antibiotics at day 1 (among survivals).

Study	Patients on antibiotics at day 1 (among survivals)				Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)	P-value	
Annane 2013	4/27	4/26	0.96 (0.27, 3.45)	0.95	Procalcitonin

Analysis 3.9. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 9 Patients on antibiotics at day 5 (survivors only).

Study	Patients on antibiotics at day 5 (survivors only)				Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)	P-value	
Annane 2013	18/27	21/26	0.83 (0.60, 1.14)	0.25	Procalcitonin

Analysis 3.10. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 10 Therapy withdrawn in hospital.

Study	Therapy withdrawn in hospital				Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)	P-value	
Shehabi 2014	38/196	35/198	1.10 (0.72, 1.66)	0.66	non-Procalcitonin

Analysis 3.11. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 11 Appropriate empirical antibiotics.

Study	Appropriate empirical antibiotics				Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)	P-value	
Dharaniyadewi 2013	95/102	88/95	1.01 (0.93, 1.09)	0.89	non-Procalcitonin

Analysis 3.12. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 12 Empirical antibiotic initiation ≤ 6 hours.

Study	Empirical antibiotic initiation ≤ 6 hours				Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)	P-value	
Dharaniyadewi 2013	83/95	36/102	2.48 (1.88, 3.25)	<0.00001	Procalcitonin

Analysis 3.13. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 13 Empirical antibiotic initiation > 6 hours.

Study	Procalcitonin (n/N)	Empirical antibiotic initiation > 6 hours		P-value	Favoured group
		non-Procalcitonin (n/N)	OR (95% CI)		
Dharaniyadewi 2013	12/95	66/102	0.20 (0.11, 0.34)	<0.00001	Procalcitonin

Analysis 3.14. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 14 Infection at day 3.

Study	Procalcitonin (n/N)	Infection at day 3		P-value	Favoured group
		non-Procalcitonin (n/N)	OR (95% CI)		
Annane 2013	1/18	1/19	1.06 (0.07, 15.64)	0.97	non-Procalcitonin

Analysis 3.15. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 15 Infection at day 5.

Study	Procalcitonin (n/N)	Infection at day 5		P-value	Favoured group
		non-Procalcitonin (n/N)	OR (95% CI)		
Annane 2013	1/18	2/19	0.53 (0.05, 5.33)	0.59	Procalcitonin

Analysis 3.16. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 16 Infection at any time point after randomization.

Study	Procalcitonin (n/N)	Infection at any time point after randomization		P-value	Favoured group
		non-Procalcitonin (n/N)	OR (95% CI)		
Annane 2013	2/18	3/19	0.70 (0.13, 3.73)	0.68	Procalcitonin

Analysis 3.17. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 17 Nasal swabs positive for methicillin-resistant *Staphylococcus aureus*.

Study	Procalcitonin (n/N)	Nasal swabs positive for methicillin-resistant <i>Staphylococcus aureus</i>		P-value	Favoured group
		non-Procalcitonin (n/N)	OR (95% CI)		
Annane 2013	1/28	2/25	0.45 (0.04, 4.63)	0.50	Procalcitonin

Analysis 3.18. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 18 Rectal swabs positive for extended-spectrum β -lactamase-resistant.

Study	Procalcitonin (n/N)	Rectal swabs positive for extended-spectrum β -lactamase-resistant		P-value	Favoured group
		non-Procalcitonin (n/N)	OR (95% CI)		
Annane 2013	1/25	0/22	2.65 (0.11, 62.00)	0.50	non-Procalcitonin

Analysis 3.19. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 19 Rectal swabs positive for *Enterobacter*, *Klebsiella*.

Study	Procalcitonin (n/N)	Rectal swabs positive for <i>Enterobacter</i> , <i>Klebsiella</i>		P-value	Favoured group
		non-Procalcitonin (n/N)	OR (95% CI)		
Annane 2013	0/24	0/24	Not estimable	Not estimable	no group

Analysis 3.20. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 20 Readmission due to secondary infection.

Study	Readmission due to secondary infection			P-value	Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)		
Shehabi 2014	6/174	12/183	0.53 [0.20, 1.37]	0.19	Procalcitonin

Analysis 3.21. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 21 Isolates with multi-resistant organisms.

Study	Isolates with multi-resistant organisms			P-value	Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	OR (95% CI)		
Shehabi 2014	45/324	43/355	1.54 (1.00, 2.36)	0.05	non-Procalcitonin

Analysis 3.22. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 22 Nosocomial infection.

Analysis 3.23. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 23 Antibiotic therapy-free days (mean, SD) - PCT vs standard care.

Study	Antibiotic therapy-free days (mean, SD) - PCT vs standard care			P-value	Favoured group
	Procalcitonin Mean (SD), N = 31	non-Procalcitonin Mean (SD), N = 37	Meand differ- ence (95% CI)		
Nobre 2008	17.4 (7.6)	13.6 (7.6)	3.80 (0.17, 7.43)	0.04	Procalcitonin

Analysis 3.24. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 24 Antibiotic therapy-free days (median, IQR) - PCT vs standard care.

Study	Antibiotic therapy-free days (median, IQR) - PCT vs standard care			P-value	Favoured group
	Procalcitonin, median (in- terquartile range [IQR])	non-Procalcitonin, median (interquartile range [IQR])			
Annane 2013	0 (0-3)	0 (0-2)	not available		Procalcitonin
Shehabi 2014	20 (11-22)	17 (7-22)	0.18		Procalcitonin

Analysis 3.25. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 25 Antibiotic therapy-free days - PCT vs CRP.

Study	Antibiotic therapy-free days - PCT vs CRP		P-value
	Procalcitonin, median/1,000 live days (interquartile range [IQR])	C-Reactive Protein, median/1,000 live days (interquartile range [IQR])	
Oliveira 2013	357.1 (0-541)	357.14 (33.3-509.2)	0.998

Analysis 3.26. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 26 Duration of first episode of antibiotic treatment (days)*.

Study	Duration of first episode of antibiotic treatment (days)*			P-value	Favoured group
	Procalcitonin Mean (SD), N = 49	non-Procalcitonin Mean (SD), N = 45	Mean difference (95% CI)		
Oliveira 2013	8.1 (3.7)	7.2 (3.5)	0.90 (-0.56, 2.36)	0.23	Procalcitonin

Analysis 3.27. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 27 Days of antibiotic exposure per 1000 inpatient days.

Study	Log [risk ratio]	Days of antibiotic exposure per 1000 inpatient days		P-value	Favoured group
		Standard error	RR (95% CI)		
Oliveira 2013	-0.079	0.059	0.92 (0.82, 1.04)	0.18	Procalcitonin

Analysis 3.28. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 28 All antibiotics total daily defined dose Irrespective of the antimicrobial.

Study	All antibiotics total daily defined dose Irrespective of the antimicrobial		P-value	Favoured group
	Procalcitonin, median (interquartile range [IQR])	non-Procalcitonin, median (interquartile range [IQR])		
Shehabi 2014	1200 (500-3000)	1500 (750-4000)	0.001	Procalcitonin

Analysis 3.29. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 29 Antibiotics "stopped earlier" (hazard ratio).

Study	Antibiotics "stopped earlier" (hazard ratio)		P-value	Favoured group
	Procalcitonin versus non-procalcitonin, hazard ratio (95% CI)			
Nobre 2008	1.9 (1.2-3.1)	0.009		Procalcitonin

Analysis 3.30. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 30 Antibiotics "stopped earlier" (hazard ratio) adjusted for disease severity.

Study	Antibiotics "stopped earlier" (hazard ratio) adjusted for disease severity		P-value	Favoured group
	Procalcitonin versus non-procalcitonin, hazard ratio (95% CI)			
Nobre 2008	1.9 (1.2-3.2)	0.009		Procalcitonin

Analysis 3.31. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 31 Time to antibiotic cessation at day 28.

Study	Time to antibiotic cessation at day 28				P	Favoured group
	Procalcitonin Median, median (interquartile range [IQR]) (n = 196)	non-procalcitonin, median (interquartile range [IQR]) (n = 198)	Hazard-ratio (95% CI)			
Shehabi 2014	9 [6-20]	11 [6-22]	1.06 (0.85-1.33)	0.59		Procalcitonin

Analysis 3.32. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 32 Duration of first episode of antibiotic treatment (days).

Study	Duration of first episode of antibiotic treatment (days)			P-value	Favoured group
	Procalcitonin, median (range)	Non-procalcitonin, median (range)	mean difference (95% CI)		
Nobre 2008	6 (4-16)	10 (3-33)	3.2 (1.1 to 5.4)	0.003	non-Procalcitonin
Oliveira 2013	7 (6.0-8.5)	6 (5.0-7.0)	not informed	0.06	procalcitonin

Analysis 3.33. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 33 Antibiotic therapy-free days according to different subgroups.

Study	Antibiotic therapy-free days according to different subgroups			P-value	Favoured group
	Procalcitonin, median (interquartile range [IQR])	non-Procalcitonin, median (interquartile range [IQR])			
Suspected sepsis					
Shehabi 2014	9 (6-17)	11 (6-18)	0.74		non-procalcitonin
Suspected septic shock					
Shehabi 2014	9 (6-22)	11 (6-24)	0.64		no-procalcitonin
Confirmed positive culture					
Shehabi 2014	13 (7-27)	13 (8-26)	0.77		none
Negative culture					
Shehabi 2014	8 (4-12)	7 (4-15)	0.94		procalcitonin
Positive blood culture					
Shehabi 2014	14 (8-23)	15 (7-27)	0.39		non-procalcitonin
Positive pulmonary culture					
Shehabi 2014	11 (7-27)	15 (8-27)	0.33		non-procalcitonin

Analysis 3.34. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 34 World Health Organization daily defined dose per 100 occupied bed days.

Study	World Health Organization daily defined dose per 100 occupied bed days			P-value	Favoured group
	Procalcitonin Mean (SD) (N = 196)	non-procalcitonin Mean (SD) (N = 198)	Mean difference (95% CI)		
Shehabi 2014	135 (93)	139 (98)	-4.00 (-22.86, 14.86)	0.68	Procalcitonin

Analysis 3.35. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 35 Antibiotics maintained for 7 days because of bacteraemia and/or a SOFA score above 10 at inclusion.

Study	Antibiotics maintained for 7 days because of bacteraemia and/or a SOFA score above 10 at inclusion				Favoured group
	Procalcitonin (n/N)	non-Procalcitonin (n/N)	RR (95% CI)	P-value	
Oliveira 2013	17/49	8/45	1.95 (0.93, 4.08)	0.08	non-Procalcitonin

Analysis 3.36. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 36 Antibiotic therapy discontinuation in the first episode of infection*.

Antibiotic therapy discontinuation in the first episode of infection*				
Study	Hazard ratio (95% CI)	P-value	Favoured group	
Oliveira 2013	1.206 (0.774–1.3)	0.1	C-reactive protein	

Analysis 3.37. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 37 Protocol overruling.

Protocol overruling					
Study	Procalcitonin (n/N)	non-Procalcitonin (n/N)	RR (95% CI)	P-value	Favoured group
Oliveira 2013	6/49	7/45	0.79 (0.29, 2.17)	0.64	Procalcitonin

Analysis 3.38. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 38 Clinical cure*.

Analysis 3.39. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 39 Total costs with antibiotics per comparison group (USD).

Total costs with antibiotics per comparison group (USD)					
Study	Procalcitonin	non-procalcitonin	Between-group absolute difference	P-value	Favoured group
Deliberato 2013	US\$ 10 608.00	US\$ 42 397.00	US\$ 31 789.00	not available	procalcitonin

Analysis 3.40. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 40 Mean cost with antibiotics + PCT kit per participant (USD).

Mean cost with antibiotics + PCT kit per participant (USD)					
Study	Procalcitonin	non-procalcitonin	Between-group absolute difference	P-value	Favoured group
Deliberato 2013	977.4	1367.64	390.24	not available	procalcitonin

Analysis 3.41. Comparison 3 PCT versus non-PCT - other outcomes of potential interest, Outcome 41 Cost reduction for antibiotic treatment.

Study	Cost reduction for antibiotic treatment		Favoured group
	Percentage of reduction	P-Value	
Schroeder 2009	17.8%	<0.01	Procalcitonin

Comparison 4. PCT versus non-PCT (standard care or CRP: ITT analysis)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at longest follow-up (imputing mortality for missing participants)	10	1215	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.73, 1.32]

Analysis 4.1. Comparison 4 PCT versus non-PCT (standard care or CRP: ITT analysis), Outcome 1 Mortality at longest follow-up (imputing mortality for missing participants).

APPENDICES

Appendix 1. CENTRAL, the Cochrane Library search strategy

- #1 procalcitonin or (calcitonin near (precursor* or polypeptide* or polypeptide)) or ((CGRP* or CALC*) near protein) or (alpha protein near human)
- #2 MeSH descriptor: [Sepsis] explode all trees
- #3 MeSH descriptor: [Septicemia] explode all trees
- #4 MeSH descriptor: [Shock, Septic] explode all trees
- #5 (sepsis or septic* or blood?stream infection* or (shock adj3 (endotoxic or toxic)))
- #6 #2 or #3 or #4 or #5
- #7 #1 and #6

Appendix 2. MEDLINE (PubMed) search strategy

#1 ("procalcitonin" [Supplementary Concept]) OR (calcitonin precursor polypeptide) OR (CGRP1 protein, mouse) OR (CALCA protein, human) OR (calcitonin/calcitonin-related polypeptide, alpha protein, human) OR (CGRP1 protein, human) OR (CALC1 protein, human)

#2 ((Sepsis) OR (Septicemia) OR (Blood stream infection) OR (Septic shock) OR (Endotoxic Shock) OR (Toxic Shock) OR (Severe sepsis))

#3 ((randomized controlled trial [pt]) OR (controlled clinical trial [pt]) OR (randomized [tiab]) OR (placebo [tiab]) OR (drug therapy [sh]) OR (randomly [tiab]) OR (trial [tiab]) OR (groups [tiab])) AND (humans [mh]))

#4 #1 and #2 and #3

Appendix 3. Embase (Ovid SP) search strategy

1. procalcitonin/ or (calcitonin adj3 (precursor* or polypeptide)).ti,ab. or ((CGRP* or CALC*) adj3 protein).ti,ab. or (alpha protein adj3 human).ti,ab.

2. sepsis/ or septicemia/ or bloodstream infection/ or septic shock/ or (sepsis or septic* or blood stream infection* or (shock adj3 (endotoxic or toxic))).ti,ab.

3. (randomized-controlled-trial/ or randomization/ or controlled-study/ or multicenter-study/ or phase-3-clinical-trial/ or phase-4-clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* or multicenter* or factorial* or placebo* or volunteer*).mp. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab. or (latin adj square).mp.) not (animals not (humans and animals)).sh.

4. 1 and 2 and 3

Appendix 4. CINAHL (EBSCOhost) search strategy

S1 procalcitonin or (calcitonin N5 (precursor* or polypeptide)) or ((CGRP* or CALC*) N5 protein) or (alpha protein N3 human)

S2 ((MH "Sepsis+") OR (MH "Shock, Septic+")) OR AB ((sepsis or septic* or blood stream infection* or (shock N3 (endotoxic or toxic))))

S3 random* or ((clinical or controlled) N3 trial*) or placebo* or multicenter* or prospective or ((blind* or mask*) N5 (single or double or triple or treble))

S4 S1 and S2 and S3

Appendix 5. LILACS (BIREME) search strategy

(calcitonin\$ and (precursor\$ or polypeptide\$ or polypeptide)) or procalcitonin

Appendix 6. Data extraction form

Extraction sheet

Effectiveness and safety of procalcitonin evaluation for reducing mortality in adult patients with sepsis, severe sepsis and septic shock

Study ID:

Date of study (year):

Review ID:

Reviewer:

Author (last name):

Locale of study:

I - ACTION

II - PARTICIPANTS

Participants

a. N:

b. Age:

c. Diagnosis (sepsis, severe sepsis, septic shock)

d. Baseline disease:

f. Gender:

g. Setting:

III - INTERVENTIONS

Intervention group (procalcitonin evaluation)

Control group (other biomarkers or no biomarker)

IV - OUTCOMES

(final or change from baseline values)

Primary outcomes

1. Mortality (at different time points)

- Intervention group (procalcitonin evaluation)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

- Control group (other biomarkers or no biomarker)

n:

N:

Mean:

Standard deviation :

Other statistics (e.g. median, odds ratio)

Secondary outcomes

2. Hospital length of stay

- Intervention group (procalcitonin evaluation)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

- Control group (other biomarkers or no biomarker)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

3. Intensive care unit (ICU) length of stay

- Intervention group (procalcitonin evaluation)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

- Control group (other biomarkers or no biomarker)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

4. Clinical severity

- Intervention group (procalcitonin evaluation)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

- Control group (other biomarkers or no biomarker)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

5. New infection/Reinfection

- Intervention group (procalcitonin evaluation)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

- Control group (other biomarkers or no biomarker)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

6. Use of antimicrobial agents

- Intervention group (procalcitonin evaluation)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

- Control group (other biomarkers or no biomarker)

n:

N:

Mean:

Standard deviation:

Other statistics (e.g. median, odds ratio)

V - METHODOLOGICAL QUALITY OF STUDY

Please mark the appropriate item and describe the reason.

1. Was the allocation sequence adequately generated? (please provide an explanation)

- 'Low risk of bias' when the authors of primary studies report methods to prevent bias.
- 'Unclear risk of bias' when the risk of bias is uncertain.
- 'High risk of bias' when the authors of primary studies clearly have not prevented the risk of bias.

2. Was allocation adequately concealed? (please provide an explanation)

- 'Low risk of bias' when the authors of primary studies report methods to prevent bias.
- 'Unclear risk of bias' when the risk of bias is uncertain.
- 'High risk of bias' when the authors of primary studies clearly have not prevented the risk of bias.

3. Was knowledge of the allocated intervention adequately prevented during the study? (please provide an explanation)

- 'Low risk of bias' when the authors of primary studies report methods to prevent bias.
- 'Unclear risk of bias' when the risk of bias is uncertain.
- 'High risk of bias' when the authors of primary studies clearly have not prevented the risk of bias.

4. Were incomplete outcome data adequately addressed? (please provide an explanation)

- 'Low risk of bias' when the authors of primary studies report methods to prevent bias.
- 'Unclear risk of bias' when the risk of bias is uncertain.
- 'High risk of bias' when the authors of primary studies clearly have not prevented the risk of bias.

5. Are reports of the study free of the suggestion of selective outcome reporting? (please provide an explanation)

- 'Low risk of bias' when the authors of primary studies report methods to prevent bias.
- 'Unclear risk of bias' when the risk of bias is uncertain.

- 'High risk of bias' when the authors of primary studies clearly have not prevented the risk of bias.
6. Was the study apparently free of other problems that could put it at high risk of bias? (please provide an explanation)
- 'Low risk of bias' when the authors of primary studies report methods to prevent bias.
 - 'Unclear risk of bias' when the risk of bias is uncertain.
 - 'High risk of bias' when the authors of primary studies clearly have not prevented the risk of bias.

VI - Observation (including non-published data)

WHAT'S NEW

Date	Event	Description
3 January 2019	Amended	Editorial team changed to Cochrane Emergency and Critical Care

CONTRIBUTIONS OF AUTHORS

Brenda NG Andriolo (BNGA), Régis B Andriolo (RBA), Reinaldo Salomão (RS), Álvaro N Atallah (ÁNA).

Conceiving of the review: BNGA, RBA, RS, ÁNA.

Co-ordinating the review: BNGA.

Undertaking manual searches: BNGA, RBA.

Screening search results: BNGA, RBA.

Organizing retrieval of papers: BNGA, RBA.

Screening retrieved papers against inclusion criteria: BNGA, RBA, RS.

Appraising the quality of papers: BNGA, RBA, RS, ÁNA.

Abstracting data from papers: BNGA, RBA, RS.

Writing to authors of papers to ask for additional information: BNGA.

Providing additional data about papers: BNGA, RBA, RS, ÁNA.

Obtaining and screening data on unpublished studies: BNGA, RBA.

Managing data for the review: BNGA, RBA, RS, ÁNA.

Entering data into Review Manager ([RevMan 5.3](#)): BNGA, RBA.

Handling RevMan statistical data: BNGA, RBA.

Performing other statistical analysis not using RevMan: BNGA, RBA.

Interpreting data: BNGA, RBA, RS, ÁNA.

Making statistical inferences: BNGA, RBA.

Writing the review: BNGA, RBA.

Performing previous work that was the foundation of the present study: BNGA, RBA, RS.

Serving as guarantor for the review (one review author): BNGA.

Taking responsibility for reading and checking the review before submission: BNGA, RBA, RS, ÁNA.

DECLARATIONS OF INTEREST

Brenda NG Andriolo: none known.

Régis B Andriolo: none known.

Reinaldo Salomão: none known.

Álvaro N Atallah: none known.

SOURCES OF SUPPORT

Internal sources

- No source of support, Other.

Own sources

External sources

- No source of support, Other.

Own sources

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

1. We selected studies and extracted data in an unblinded and dependent fashion (not independently, as previously stated in the protocol) ([Silva 2014](#)).
2. Primary outcomes: We included mortality at longest follow-up as an additional primary outcome because absence of evidence on mortality often results from insufficient power, as well as from clinical and methodological heterogeneity associated with primary studies, although the latter was not the specific case for this systematic review.
3. We performed a post hoc sensitivity analysis to test the estimate of effect of the intervention by removing a study that made a singular comparison: procalcitonin versus C-reactive protein.
4. We changed the "Synthesis of the quality of the body of evidence" section from:
 - "We will use the principles of the GRADE system ([Guyatt 2008](#)) to assess the quality of the body of evidence associated with mortality, hospital and intensive care unit length of stay, clinical severity, new infection/reinfection and use of antimicrobial agents. We will also construct a 'Summary of findings' (SoF) table using the GRADE software. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence reflects within-study risk of bias (methodological quality), directness of evidence, heterogeneity of data, precision of effect estimates and risk of publication bias" to:
 - "We used the principles of the GRADE approach ([Guyatt 2008](#)) to assess the quality of the body of evidence for our primary outcomes of mortality at 28 days, mortality at ICU discharge, mortality at hospital discharge and time receiving antimicrobial therapy. We imported effect estimates from [RevMan 5.3](#) to GRADE profiler ([GRADEpro 2014](#)) to create [Summary of findings for the main comparison](#). This table provides outcome-specific information concerning the overall quality of evidence from studies included in the comparison, the magnitude of effect of interventions examined and the sum of available data on outcomes that we considered. The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item assessed. The quality of a body of evidence is based on different items, which reflect within-study risk of bias (methodological quality), directness of evidence, heterogeneity of data, precision of effect estimates and risk of publication bias. Thus, we considered each of these items as having 'no limitation', 'serious limitation' or 'very serious limitation' (by downgrading them respectively for one or two levels), resulting in one of the following four overall qualities of evidence for each outcome: 'high', 'moderate', 'low' or 'very low' quality."

NOTES

Brenda NG Andriolo was previously known as Brenda NG Silva.

INDEX TERMS

Medical Subject Headings (MeSH)

Anti-Bacterial Agents [therapeutic use]; Biomarkers [blood]; Calcitonin [*blood]; Intensive Care Units; Patient Discharge; Randomized Controlled Trials as Topic; Sepsis [*blood] [drug therapy] [*mortality]; Shock, Septic [blood] [drug therapy] [mortality]; Time Factors

MeSH check words

Adult; Humans